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Abstract 
 
Infantile hemangioma (IH) is a vascular neoplasm that affects 4-10 percent of 
infants.  Propranolol, a non-selective β-adrenergic receptor (AR) antagonist, was 
serendipitously discovered to accelerate regression of IH in 2008; however, its 
mechanism in IH is unclear. 
A number of approaches were used to investigate the mechanism(s) by which 
propranolol accelerates the involution of IH.  Two of the likely targets of propranolol, β1 
and β2-ARs, were found expressed in IH tissues by quantitative real time polymerase 
chain reaction (qRT-PCR).  In vitro contractility assays were developed to examine 
effects of propranolol on cellular activities, and they showed that wrinkles formed by 
hemangioma-derived pericytes (Hem-Pericytes) relaxed in response to epinephrine, but 
this was strongly inhibited if propranolol was added 5 minutes before epinephrine.  
These responses were blunted by silencing β2-AR with siRNA.  Propranolol had no 
effect on the contractility of placental or retinal pericytes in this assay.  Propranolol also 
blocked proliferation of Hem-Pericytes and hemangioma-derived endothelial cells 
(HemECs), but not stem cells (HemSCs). 
In order to reproduce the clinical effect of propranolol on IH patients, a murine 
model of IH was utilized.  HemECs and Hem-Pericytes suspended in Matrigel were 
implanted in mice and allowed to form blood vessels.  At 7 days, vascular perfusion of  
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the cell/Matrigel implants was verified; mice were divided into two groups and treated 
with vehicle or propranolol for 7 days.  Contrast-enhanced micro-ultrasonography of the 
implants showed a significantly decreased vascular volume in propranolol-treated mice, 
but no reduction in those treated with vehicle.  These experiments indicated that 
propranolol may affect contractility of Hem-Pericytes to reduce vascular volume of IH, to 
accomplish quick improvement seen in patients, and they identified HemECs, Hem-
Pericytes and β2-AR as likely targets of propranolol. 
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Chapter I 
Characteristics of infantile hemangioma 
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1.1 An introduction to vascular anomalies 
Vascular anomalies are divided into tumors and malformations.  Tumors, or abnormally 
enlarged lesions, include pyogenic granuloma, Kaposiform hemangioendothelioma, 
congenital hemangioma and infantile hemangioma (IH).  Pyogenic granuloma usually 
appears on superficial skin and bleeds easily.  Kaposiform hemangioendothelioma is 
associated with a low number of platelets, which predisposes patients to frequent 
bleeding.  Congenital hemangioma is notable at birth; it regresses on its own (rapidly 
involuting) or does not (non-involuting).  Malformations can occur at various sites 
including arteries, arteriovenous connections, veins, lymphatic vessels and capillaries.  
Malformations with arterial component exhibit fast blood flow, whereas those with 
venous component exhibit slow blood flow.  Depending on sites of occurrence, 
malformations can lead to symptoms such as color change from normal skin, swelling 
and pain (Figure 1; Mulliken, Fishman et al.  2000; Hammill, Wentzel et al.  2011). 
 
 
Figure 1.  Vascular anomalies classification. 
Pediatric Blood Cancer.  57(6):  1018-24, 2011, Copyright Wiley Periodicals 
Inc.  This material is reproduced with permission of John Wiley & Sons, Inc. 
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An introduction to IH 
IH is the most common and best-studied vascular tumor.  IH is a pediatric vascular 
tumor that appears as red, raised flesh a few weeks after birth in 5-10 % of neonates, 
and it is more common in the prematurely-born and in females.  Approximately two-
thirds of lesions occur in head and neck region, with the rest appearing elsewhere on 
the skin or deep inside the body- e.g., liver, trachea and parotid glands, etc.  IH is 
characterized by three phases, proliferating, involuting and involuted.  The vascular 
lesion grows the fastest during proliferating phase, stops growing during involuting 
phase and shrinks in involuted phase.  In terms of vascular architecture, proliferating 
phase is characterized by dense, disorganized vessels consisting of plump endothelial 
cells and lasts until age 9-12 months.  Involuting phase is characterized by enlarged, 
well-organized vessels consisting of flattened endothelial cells and follows the 
proliferating phase for 3-5 years.  In both proliferating and involuting phases, numerous 
pericytes have been noted to surround IH vessels.  Finally, involuted phase is 
characterized by few vessels with an abundance of adipocytes and lasts until age 5-8 
years (Mulliken, Fishman et al.  2000). 
 
Deciphering the origin of IH 
Several hypotheses have been proposed about the origin of IH.  A group of researchers 
examined methylation patterns in HemECs.  The cells displayed a non-random pattern 
of X-chromosomal inactivation, indicating clonality and lending credence to a genetic 
basis for IH (Boye, Yu et al.  2001; Walter, North et al.  2002).  
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Others believe that the tumor microenvironment contributes to the genesis of IH.  
A group of researchers examined formalin-fixed, paraffin-embedded hemangioma 
tissues from the 3 phases.  They noted that the epidermis overlying proliferative phase 
hemangiomas expressed higher levels of pro-angiogenic factors, such as basic 
fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), but 
lower levels of an inhibitor of angiogenesis, such as interferon-β (IFN-β), compared to 
the epidermis overlying involuted phase.  Therefore, they reasoned that the interaction 
and imbalance of angiogenic signals between IH and adjacent epidermis are key factors 
in the origin and pathogenesis of IH (Bielenberg, Bucana et al.  1999). 
Others have postulated that IH arises from fetal placental cells based on shared 
immunophenotypes.  They noted that IH and placenta share markers such as glucose 
transporter-1 (GLUT1), Lewis Y antigen and merosin, which are not expressed by the 
normal vasculature of skin.  If pregnant mothers were to receive chorionic villus 
sampling to diagnose potential genetic abnormalities, placental cells might be dislodged 
and embolize to fetus through right-to-left shunts, normal for fetal circulation.  These 
dislodged and embolized placental cells may give rise to IH in the fetus (North, Waner 
et al.  2002).  Although some have reported an increased incidence of IH in those 
whose mothers underwent chorionic villus sampling (Kaplan, Normandin et al.  1990; 
Burton, Schulz et al.  1995), a positive correlation with the procedure was not verified in 
a multi-center study of 1058 children with hemangioma (Haggstrom, Drolet et al.  2007).  
Overall, researchers have made strides, but more work needs to be done to clarify the 
origin of IH. 
  
5 
 
1.2 Molecular pathways implicated in IH 
Vascular endothelial growth factor (VEGF) 
VEGF is a central regulator of normal developmental and pathological angiogenesis, 
and several studies have implicated VEGF and its receptors in IH.  A summary of the 
key players and mechanisms of the VEGF pathway in angiogenesis are provided here. 
The mammalian VEGF family consists of VEGF-A, -B, -C and -D.  Among them, 
VEGF-A has been the most well-characterized, with roles including endothelial cell 
survival and morphogenesis, cellular migration to form vessel lumen and stimulation of 
vessel dilation and permeability.  Alternative splicing of the 8 exons of VEGF-A gives 
rise to isoforms of different lengths, which include VEGF-A121, -A145, -A165, -A189 and -
A206.  These isoforms differ in their inclusion of exons 6 and/or 7, which encode domains 
for binding heparan sulfate proteoglycans (HSPGs) and neuropilins (NRPs), co-
receptors of VEGF, in the extracellular matrix.  As a result, VEGF-A121 is very diffusible, 
VEGF-A165 less diffusible and VEGF-A206 even less diffusible but with strong 
interactions via binding HSPGs and NRPs in the matrix.  Relative proportions of these 
isoforms affect VEGF-A gradients and its levels.  VEGF-B, -C and –D were discovered 
after VEGF-A, and their lengths range 167-400 amino acids.  While VEGF-B has not 
been as prominently featured in angiogenesis as VEGF-A, it has been reported to be 
important in embryonic cardiac angiogenesis, and its expression was detected IH 
(Boscolo, Mulliken et al.  2011).  VEGF-C and –D have been reported to be involved in 
lymphangiogenesis.  Although not studied as extensively as VEGFs, placental growth 
factor (PlGF) has been reported to be involved in angiogenesis, too (Bautch 2012; 
Olsson, Dimberg et al.  2006).  
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VEGF dimers bind vascular endothelial growth factor receptors (VEGFRs), which 
are referred as VEGFR-1, -2 and -3.  Alternative names for VEGFRs are Flt-1 for 
VEGFR-1, Flk-1/KDR for VEGFR-2 and Flt-4 for VEGFR-3.  VEGF-A binds VEGFR-1 
and -2, VEGF-B binds VEGFR-1 and VEGF-C and-D each binds VEGFR-2 and -3.  
VEGF-E, a non-human form, binds VEGFR-2, and PlGFs bind VEGFR-1.  Interaction of 
VEGFs with VEGFRs and co-receptors HSPGs and NRPs influences parameters such 
as VEGF gradient and its duration of signaling.  VEGFRs are tyrosine kinase receptors 
that have an extracellular region with 7 immunoglobulin-like domains for binding VEGF, 
a single transmembrane region and a split intracellular tyrosine kinase region.  Upon 
binding of dimerized ligands, VEGFRs dimerize and trans-autophosphorylate at specific 
tyrosines in the cytoplasmic domains, such as tyrosines 951, 1175 and 1214 for 
VEGFR-2.  Creation of phosphorylated tyrosines (phosphotyrosines) within the kinase 
domain increases the kinase activity of the receptor, while phosphotyrosines outside the 
kinase domain create high-affinity docking sites for binding of signaling proteins, such 
as phosphoinositide 3-kinase (PI 3-kinase), phospholipase C-γ (PLC-γ)  and adaptors, 
which have SH2 or PTB domains for binding phosphotyrosines. 
Signaling through the three VEGFRs serves diverse functions.  For instance, 
VEGFR-1 is involved in recruitment of hematopoietic progenitors, migration of 
monocytes and macrophages, and it has been noted as a decoy receptor for VEGFR-2 
by reducing the availability of VEGF-A that can bind VEGFR-2.  VEGFR-2 is involved in 
activities such as endothelial cell survival and dilation, growth and permeability of 
vessels.  VEGFR-3 is noted to be important in lymphangiogenesis (Bautch 2012; 
Olsson, Dimberg et al.  2006; Figure 2).  
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An example of angiogenesis driven by VEGF-A occurs in hypoxia, which is an 
important physiologic and pathologic regulator of VEGF-A.  Low oxygen levels induce 
an intracellular accumulation of a gene regulatory protein, hypoxia-inducible factor 1α 
(HIF1α), which dimerizes with HIF1β.  HIF1α/β complex translocates to the nucleus, 
binds VEGF promoter to stimulate its transcription.  VEGF-A in turn stimulates 
neighboring endothelial cells to proliferate, to produce proteases to digest basal lamina 
of existing vessels and to form vessel sprouts, which consist of a tip cell and stalk cells 
behind it.  The tip cells respond to VEGF-A gradient by moving towards it using their 
filopodia, while stalk cells respond to VEGF-A levels by proliferating and forming vessel 
lumens.  The newly-formed vessels transport blood to the hypoxic tissue, so more 
oxygen is delivered.  As a result, HIF1α is hydroxylated at proline residues, allowing 
their recognition for ubiquitination and subsequent targeting for degradation, eventually 
decreasing VEGF-A production.  Thus, VEGF-A production is controlled by negative 
 
Figure 2.  Ligands, VEGFRs and downstream effects . 
Alternative names for VEGFRs are indicated in parentheses.  
Co-receptors HSPGs (not shown) and NRPs increase binding 
affinity of ligands to VEGFRs. 
Reproduced with permission from J Clin Oncol.  23(5):  1011-
27, 2005, Copyright American Society of Clinical Oncology. 
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feedback, and it plays a key role during angiogenesis in response to hypoxia (Gerhardt, 
Golding et al.  2003). 
Researchers have been interested in clinical applications of angiogenesis.  For 
instance, promotion of vessel growth is desired if healthy tissue has died due to 
decreased oxygen supply, in conditions such as heart attack and stroke.  On the other 
hand, inhibition of vessel growth is preferred if angiogenesis is pathologic in select 
areas, in conditions such as diabetes-related vision changes and cancer.  A well-known 
anti-VEGF therapeutic is Bevacizumab, also known as Avastin.  It is a VEGF-A-
neutralizing antibody, and if combined with chemotherapy, it prolongs survival of 
patients with cancer in brain, colon, kidneys and lungs (Olsson, Dimberg et al.  2006). 
Thus, VEGF and its signaling through VEGFRs present wide areas of research, 
which may encompass IH pathogenesis.  Indeed, a group of researchers found that 
cells cultured from surgically resected hemangiomas released VEGF and VEGFR-2.  
Anti-VEGF IgG and antisense oligonucleotides directed against the translation initiation 
codon of VEGFR-2 reduced proliferation of these cells.  Therefore, VEGF was 
postulated to be a key molecule in the pathogenesis of IH (Berard, Sordello et al.  
1997).  In addition, VEGF-A levels were elevated in serum of patients with proliferating 
phase IH compared to age-matched controls (Zhang, Lin et al.  2005; Kleinman, 
Greives et al.  2007); in terms of location, VEGF-A expression was noted in stroma of IH 
from proliferating phase (Greenberger, Boscolo et al.  2010).  On the other hand, 
VEGFR-1 expression was noted to be low in hemangioma tissues from both 
proliferating and involuting phases compared to a non-pathologic tissue like placenta 
(Picard, Boscolo et al.  2008).  Regardless of its low expression, signaling through  
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VEGFR-1 has been noted to important in formation of hemangioma vessels in a murine 
model of IH (Boscolo, Mulliken et al.  2011). 
A group of researchers published data showing hyperphosphorylated VEGFR-2 
in hemangioma-derived endothelial cells compared to human dermal microvascular 
endothelial cells (HDMECs).  In hemangioma-derived endothelial cells from some 
patients, they found mutations in the genes encoding VEGFR-2 and tumor endothelial 
marker-8 (TEM8).  They hypothesized that the mutated VEGFR-2 and TEM8 help 
downregulate nuclear factor of activated T cells (NFAT), a transcription factor required 
for VEGFR-1 activity regulation.  Expression of VEGFR-1 in hemangioma-derived 
endothelial cells was reduced compared to non-hemangioma-derived cells like 
HDMECs and human umbilical vein endothelial cells (HUVECs).  With decreased 
numbers of VEGFR-1, VEGF more likely binds VEGFR-2 to trigger hyper-proliferation of 
hemangioma-derived endothelial cells (Jinnin, Medici et al.  2008).  Traits of 
hemangioma-derived cells will be explained further in Section 1.3. 
 
Notch signaling pathway 
Notch pathway plays important roles in controlling cell fates in development of various 
organs in mammals, which possess 4 different receptors, Notch1-4.  Notch receptors 
consist of 36 epidermal growth factor (EGF)-like domains in the extracellular region, a 
single-pass transmembrane region and an intracellular region.  Their ligands include 
Jagged and Delta proteins. 
As noted above, Notch receptor plays important roles in controlling cell fates, and 
a well-known example involves neural cells in Drosophila.  Among progenitor cells, one  
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may become a neural cell, and this cell inhibits its neighbors from also becoming neural 
cells.  This process, called lateral inhibition, is accomplished by Notch receptor signaling 
activated by Delta, a single-pass transmembrane signal protein with 9 EGF-like 
domains.  On its surface, a future neural cell displays Delta, which is bound by Notch 
receptors on its neighboring cells that are inhibited from becoming neural cells. 
Notch receptor signaling by Delta is facilitated by 3 proteolytic cleavages, the last 
2 of which occur after binding by Delta.  First, Notch receptor is cleaved in the Golgi 
apparatus by Furin-like protease to generate a heterodimer and transported to cell 
surface.  Delta ligand on the future neural cell and Notch receptor on a neighboring cell 
bind through their EGF-like domains, which is followed by a second cleavage with 
ADAM family protease 10 or 17 in the extracellular region of Notch receptor.  While the 
bound Delta-Notch is endocytosed by the future neural cell, a third cleavage occurs on 
the transmembrane region of Notch receptor by γ-secretase.  Notch intracellular domain 
(NICD) migrates to nucleus of a neighboring cell to bind responsive elements in target 
genes and activates their transcription with regulatory proteins.  Notch signaling leads to 
inhibition of neural cell differentiation and maintenance of a neighboring cell as a 
progenitor, while neural cell differentiation occurs in the Delta-expressing cell (Figure 3; 
Bray 2006; Musse, Meloty-Kapella et al.  2012).  
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Notch signaling and lateral inhibition is directly relevant to angiogenesis.  As 
noted above, vessel sprouts form in response to VEGF-A, and sprouts consist of a tip 
cell and stalk cells.  VEGF-A binds VEGFR-2 to induce Delta-like 4 expression in a 
future tip cell; Delta-like 4 then binds Notch receptors in its neighbors, which become 
stalk cells.  Selection of tip and stalk cells is aided by the Fringe family of 
glycosyltransferases; they are abundantly expressed in sprouts and glycosylate Notch 
at EGF-like domains.  This modification enhances Notch signaling by Delta-like 4, but 
reduces Notch signaling upon binding of Jagged1, another Notch ligand.  Therefore, 
Jagged1, highly expressed in stalk cells, acts as an antagonist of Delta-like 4, so that 
stalk cells do not activate Notch signaling in adjacent tip cells.  Jagged1 also interferes 
 
Figure 3.  Notch receptor signaling overview. 
(a) In the absence of Notch signaling, RBP-J, a regulatory 
protein, is a transcriptional repressor.  The first proteolytic 
cleavage creates a heterodimeric receptor, with 
extracellular Notch and Notch intracellular domain (NICD). 
(b) Ligand (Delta or Jagged) binding induces 2 additional 
proteolytic cleavages.  NICD migrates to nucleus to bind 
RBP-J and activate transcription of target genes. 
Reproduced with permission from Trends Mol Med.  
11(11):  496-502, 2005, Copyright Elsevier.  
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with signaling of Delta-like 4 through Notch in stalk cells to help maintain VEGFRs, so 
that stalk cells proliferate in response to VEGF-A.  Thus, in the sprouts responding to 
VEGF-A, Notch signaling is low in tip cells, but high in stalk cells.  In support of this 
hypothesis, inhibition of Notch signaling increased numbers of tip cells, but activation of 
Notch signaling reduced numbers of tip cells (Hellström, Phng et al.  2007; Benedito, 
Roca et al.  2009). 
In addition to its role in angiogenesis, Notch signaling was found to be potentially 
relevant in IH.  Laser capture microdissection and genome-wide transcriptional profiling 
of vessels from proliferating IHs showed that RNA levels of Jagged1 and Notch4 were 
upregulated 6- and 3-fold, respectively, compared to placental vessels (Calicchio, 
Collins et al.  2009).  In support of these findings, Jagged1 was found important in 
differentiation of hemangioma-derived cells and hemangioma vessel formation in a 
murine model of IH (Boscolo, Stewart et al.  2011).  In addition, researchers noted that 
while RNA levels of Notch4 and Jagged1 were elevated in involuting IHs compared to 
normal skin and placenta, immunostaining for Notch3 showed change in location by 
phases- in interstitial cells outside hemangioma vessels in proliferating phase, but in 
pericytes in involuting phase (Wu, Adepoju et al.  2010).  In a follow-up study, 
expression of Notch target genes, including Hes1, was detected in hemangioma-derived 
cells (Adepoju, Wong et al.  2011).  Thus, similar to its roles in neural cell determination 
and vessel sprouting, Notch may play a role in intercellular communications of IH.  
Laser capture microdissection and genome-wide transcriptional profiling of vessels from 
proliferating IHs also showed that RNA levels of another molecule, angiopoietin-2, was  
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upregulated 33-fold compared to placental vessels.  The potential relevance of this 
finding in IH will be discussed in the following section. 
 
Angiopoietins and Tie receptors 
Angiopoietins are divided into angiopoietins-1-4, and they bind Tie receptor tyrosine 
kinases.  Tie1 and 2 are expressed in endothelial cells, and the binding of angiopoietin-
1 or -2 on Tie2 has been well-characterized.  In contrast, effects of angiopoietins-3 and -
4 binding on Tie receptors and Tie1 receptor signaling have not been as well-
characterized.  Hence, this section will focus on angiopoietins-1, -2 and Tie2 receptor. 
  Tyrosine kinase receptors such as Tie2 have an extracellular region for binding 
ligands, a single transmembrane region and an intracellular tyrosine kinase region.  
Upon binding of angiopoietin-1 ligands, Tie2 receptors multimerize, trans-
autophosphorylate and create phosphotyrosine docking sites.  PI 3-kinase is recruited 
to activated Tie2 receptors and docked on such phosphotyrosines.  PI 3-kinase creates 
phosphoinositides such as PI(3,4,5)P3, upon which Akt is docked with its pleckstrin 
homology domain for phosphorylation and activation by entities such as 
phosphoinositol-dependent kinase and mammalian target of rapamycin (mTOR).  
Activated Akt phosphorylates numerous targets on serines and threonines including 
Bad, a pro-apoptotic protein.  Unphophorylated Bad binds Bcl2, an anti-apoptotic 
protein, to keep it inactive; upon phophorylation, Bad is bound by cytosolic protein 14-3-
3, and Bcl2 is released from its inactive state, so apoptosis is inhibited (Downward 
2004).  Another effect of angiopoietin-1 signaling through Tie2 receptors is inhibition of 
nuclear factor-kB (NF-kB), which is involved in inflammation.  Thus, endothelial cell  
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survival is promoted, and vessels are stabilized by diminishment of inflammatory 
responses.  Researchers have postulated that angiopoietin-1 signaling induces trans-
association of Tie2 at cell-cell junctions, promoting endothelial cell survival and anti-
inflammation.  On the other hand, extracellular cellular matrix-bound Tie2 signaling, in 
the absence of cell-cell junctions, promotes endothelial cell proliferation and migration 
(Figure 4; Fiedler and Augustin 2006; Huang, Bhat et al.  2010; Eklund and Saharinen 
2013). 
 
 
Figure 4.  Angiopoietins signaling through Tie receptors. 
Angiopoietin-1 multimers bind to Tie2, which multimerize and 
trans-autophosphorylate to activate targets.  Angiopoietin-2 exerts 
antagonistic actions but can act as a partial Tie2 agonist in some 
contexts (dashed arrow).  Activated Tie2 stimulates Tie1, which 
interferes with Tie2 signaling by angiopoietin-1.  Purple shapes 
indicate action through matrix-bound Tie2, whereas gold and blue 
shapes indicate action through trans-associated Tie2. 
Reproduced with permission from Nat Rev Cancer.  10(8):  575-
85, 2010, Copyright Nature Publishing Group. 
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Interestingly, angiopoietin-1 signaling through Tie2 receptors leads to inhibition of 
angiopoietin-2 expression and secretion, which indicates potentially antagonistic actions 
of angiopoietins-1 and -2.  In affirmation of this possibility, angiopoietin-2 binding to Tie2 
receptors does not lead to rapid autophosphorylation of Tie2 receptor; therefore, in 
contrast to angiopoietin-1 signaling, endothelial cell apoptosis is promoted, and vessels 
are destabilized and become more receptive to inflammatory responses (Figure 4; 
Fiedler and Augustin 2006; Huang, Bhat et al.  2010). 
To add complexity to angiopoietins-1 and -2 signaling, these responses were 
found to be influenced by VEGF.  Large amounts of angiopoietin-2 mRNA were noted 
near degenerated vessels of unfertilized rat ovarian follicles with low VEGF mRNA 
levels.  However, in the presence of high levels of angiopoietin-2 and VEGF mRNAs, 
numerous vessel sprouts were detected.  Researchers hypothesized that in the 
presence of VEGF, angiopoietin-2 promotes vessel sprouting by blocking the vessel 
stabilization effect of angiopoietin-1.  In the absence of VEGF, antagonism of 
angiopoietin-1 by angiopoietin-2 leads to vessel destabilization and regression (Koh 
2013; Maisonpierre, Suri et al.  1997). 
  Besides the antagonistic actions of angiopoietins-1 and -2 on the common 
receptor Tie2, another point of interest is different locations of expression of 
angiopoietins-1 and -2.  Angiopoietin-1 is mostly expressed in non-endothelial cells 
such as fibroblasts, smooth muscle cells and pericytes.  On the other hand, 
angiopoietin-2 is synthesized in endothelial cells, stored and released from storage 
granules called Weibel-Palade bodies.  The significance of these differences is unclear, 
but it may be tied to the contrasting effects that angiopoietin-1 or -2 accomplishes  
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through Tie2 signaling.  For instance, angiopoietin-1 expressed by a pericyte precursor 
binds Tie2 receptor on endothelial cells.  This leads to endothelial cell survival, pericyte 
precursor attachment and stabilization of vessels, which are expected in normal, 
physiologic processes of angiogenesis such as wound healing (Gaengel, Genové et al.  
2008). 
In contrast, actions of angiopoietin-2 in animal studies provide clues on 
pathologic angiogenesis.  Endogenous angiopoietin-2 is upregulated in retinas of 
animals with diabetes.  The vessels in retinas show pericyte loss and degeneration.  
Similarly, exogenous angiopoietin-2, either by injection of recombinant protein into 
retinas or transgenic overexpression selectively in retinas, leads to a similar phenotype 
(Hammes, Lin et al.  2004; Feng, vom Hagen et al.  2007).  As noted above, in the 
presence of VEGF, angiopoietin-2 signaling promotes formation of vessel sprouts, 
whereas in the absence of VEGF, angiopoietin-2 signaling promotes endothelial cell 
apoptosis and vessel destabilization.  These findings may have relevance in IH because 
low availability of VEGFR-1 in hemangioma-derived endothelial cells directs VEGF-A to 
VEGFR-2, leading to cellular hyperproliferation (Jinnin, Medici et al.  2008).  Vessel 
sprouting is induced by upregulated angiopoietin-2 in the presence of VEGF, so the 
combination of angiopoietin-2 and VEGF may lead to pathological angiogenesis as in 
IH. 
Researchers have confirmed the importance of angiopoietin signaling through 
Tie2 receptor in IH.  For instance, hemangioma-derived endothelial cells expressed 
higher levels of Tie2 compared to HDMECs (Yu, Varughese et al.  2001).  As described 
above, RNA levels of angiopoietin-2 was upregulated 33-fold in endothelium of  
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proliferating IHs compared to placental vessels (Calicchio, Collins et al.  2009).  On the 
other hand, angiopoietin-1 levels were low in hemangioma-derived pericytes compared 
to non-hemangioma pericytes (Boscolo, Mulliken et al.  2013).  An in-depth discussion 
of hemangioma-derived cells will follow in Section 1.3. 
Tie2 and VEGFR are both receptors with tyrosine kinase domains in the 
intracellular region.  Multimer ligand binding induces proximity of receptors, and trans-
autophosphorylation occurs by kinase domains to initiate downstream signaling.  In 
addition, signaling with angiopoietins-1 and -2 through Tie2 receptor influences cellular 
interactions in angiogenesis, somewhat similar to effects brought on by Delta signaling 
through Notch receptors.  Thus, signaling through VEGFR, Notch and Tie receptors 
converge in IH. 
 
Other characteristics of IH 
GLUT1, an erythrocyte-type glucose transporter protein, was found to be a useful 
diagnostic marker for IH in all 3 phases.  In a retrospective study, 97% of IHs had 
endothelial GLUT1 immunoreactivity by immunohistochemistry (IHC), whereas normal 
skin or other vascular anomalies such as arteriovenous and venous malformations and 
port-wine stain had not expressed GLUT1.  GLUT1 is expressed in placenta, which led 
researchers to speculate on a placental origin for IH (North, Waner et al.  2000).  It 
should be noted that even though most vessels in IH express GLUT1, some endothelial 
cells are GLUT1
+, whereas others are GLUT1
-.  This dichotomy may indicate different 
origins for cells in IH and underscores the need to clarify the origin of IH.  
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As noted above, IH occurs more frequently in females, so high levels of serum 
estrogen in IH patients were suspected by some to be correlated with IH (Zhou, Wang 
et al.  1991).  Researchers detected that hemangioma-derived endothelial cells grew 
more rapidly in the presence of estrogen, but this was suppressed by tamoxifen, an 
antagonist of the estrogen receptor (Xiao, Hong et al.  1999).  The same group of 
researchers noted that estrogen increased proliferation of hemangioma-derived 
endothelial cells, but not as highly as VEGF.  They also detected that estrogen and 
VEGF synergistically increased proliferation (Xiao, Liu et al.  2004).  Although these 
findings were intriguing, hormonal effects in IH have not been studied actively. 
E-selectin, an endothelial-cell-specific leukocyte adhesion molecule, was highly 
expressed in proliferating phase IH tissues and co-localized with dividing endothelial 
cells, as determined by Ki67
+ immunoreactivity.  E-selectin immunoreactivity was also 
high in placenta and neonatal foreskin, tissues with ongoing angiogenesis, but low in 
involuting phase IH tissues and adult skin.  These findings indicated E-selectin as a 
diagnostic marker for proliferating endothelium and its possible role in angiogenesis 
(Kräling, Razon et al.  1996).  Indeed, recombinant E-selectin and E-selectin
+ 
hemangioma-derived endothelial cells enhanced migration and adhesion of 
hemangioma-derived stem cells in vitro.  Blocking mAb against E-selectin did not affect 
proliferation of hemangioma-derived stem cells, but the same antibody inhibited 
formation of blood vessels when hemangioma-derived endothelial cells and 
hemangioma-derived stem cells were implanted in Matrigel.  These findings identified E-
selectin as an important modulator of interactions between hemangioma-derived 
endothelial cells and hemangioma-derived stem cells (Smadja, Mulliken et al.  2012).   
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As noted above, like E-selectin, angiopoietin-2 was highly expressed in endothelium of 
proliferating phase IH tissues.  This commonality could indicate their shared roles in 
regulating pathogenesis of IH. 
 
1.3 Hemangioma-derived cells and their characteristics 
Endothelial cells, pericytes and stem cells have been isolated from hemagioma tumor 
specimens.  The Bischoff Laboratory has developed the following terminologies for 
these cells:  hemangioma-derived endothelial cell (HemEC), hemangioma-derived 
pericyte (Hem-Pericyte) and hemangioma-derived stem cell (HemSC).  Each cell type 
has distinct characteristics. 
 
HemECs 
HemECs display endothelial markers such as CD31, CD146, E-selectin and VE-
cadherin.  As noted above, HemECs displayed a non-random pattern of X-chromosomal 
inactivation, indicating clonality.  They proliferated faster than mature human ECs, such 
as HDMECs with or without exogenous VEGF.  They showed increased migration upon 
treatment with an angiogenesis inhibitor endostatin, which was the opposite of HDMECs 
(Boye, Yu et al.  2001). 
The Bischoff Laboratory researchers also found that HemECs expressed higher 
levels of Tie2 compared to normal ECs such as HDMECs.  Higher numbers of HemECs 
than HDMECs migrated in response to angiopoietin-1.  HemECs also proliferated faster 
than HDMECs in response to angiopoietin-1.  On the other hand, both HemECs and 
HDMECs had undetectable levels of VEGF and angiopoietin-1 but similar levels of  
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CD31, VE-cadherin, Tie1, VEGFR-1 and VEGFR-2.  As was noted in endothelium of 
hemangiomas from proliferating phase, angiopoietin-2 was expressed in HemECs (Yu, 
Varughese et al.  2001). 
Notch signaling pathway plays important roles in neural cell determination and 
vessel sprouting, and a group of researchers noted that RNA levels of Jagged1, a Notch 
ligand, were higher in HemECs compared to HDMECs.  On the other hand, RNA levels 
of Delta-like 4, another Notch ligand, were lower in HemECs compared to HDMECs 
(Wu, Adepoju et al.  2010).  While the significance of these findings wasn’t clear, they 
hinted that Notch signaling was present and active in IH. 
 
Hem-Pericytes 
Hem-Pericytes display markers of pericytes like alpha smooth muscle actin (αSMA), 
calponin, neural glial antigen-2 (NG2), platelet-derived growth factor receptor β 
(PDGFR-β) and smooth muscle myosin heavy chain (smMHC).  These markers are 
expressed by perivascular cells in proliferating phase of IH, so cultured Hem-Pericytes 
match expression pattern of pericytes in IH tissue.  Hem-Pericytes isolated from 
proliferating phase of IH displayed lower levels of baseline contractility in vitro, 
compared to those from involuting phase of IH and human retinal pericytes.  Also, 
compared to human retinal pericytes, they express lower angiopoietin-1 levels.  In co-
culture assays, Hem-Pericytes were unable to reduce proliferation or migration of 
endothelial cells.  Thus, Hem-Pericytes surround vessels, but they are unable to 
stabilize endothelial cell growth and migration.  In other words, Hem-Pericytes display 
reduced ability to support mature, stable vessels (Boscolo, Mulliken et al.  2013).   
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Compared to HemECs and HemSCs, less is known about Hem-Pericytes because they 
were discovered relatively recently. 
 
HemSCs 
HemSCs display stem cell markers such as CD133 and Oct-4, express mesenchymal 
marker CD90, but do not express endothelial, hematopoietic or pericytic cell markers.  
The Bischoff Laboratory researchers found that the CD133
+ cells (HemSCs) generated 
human, GLUT1
+ blood vessels in immunodeficient mice after 7 days.  After two months, 
the number of blood vessels decreased, while the number of adipocytes increased.  
GFP-tagged lentivirus was used to label HemSCs, so they could be tracked in vivo.  
This allowed confirmation that the HemSCs formed the blood vessels and then 
adipocytes in immunodeficient mice.  Thus, HemSCs recapitulated certain aspects of 
the phases of IH, blood vessels followed by fatty tissue, in an expedited time frame.  
HemSCs can self-renew, and they can differentiate to adipocytes, endothelial cells, 
pericyte/smooth muscle cells and also neuroglial cells (Khan, Boscolo et al.  2008).  
Although they comprise fewer than 1% of cells from hemangioma tissue, in tissue 
culture they grow the fastest and express the highest levels of VEGF-A among the 3 
hemangioma-derived cell types. 
The Bischoff Laboratory researchers also noted that VEGF-A or VEGF-B can 
bind VEGFR-1 on HemSCs.  This leads to phosphorylation of extracellular signal-
regulated kinases 1/2 (ERK 1/2) and promotes differentiation of HemSCs to HemECs.  
Suppression of VEGFR-1 with shRNA prevented this differentiation and decreased  
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formation of blood vessels in vivo.  Therefore, VEGFR-1 was determined critical for 
differentiation of HemSCs to HemECs (Boscolo, Mulliken et al.  2011). 
More discoveries were made concerning differentiation of HemSCs to other cell 
types.  The Bischoff Laboratory researchers used GFP-labeled HemSCs to find that 
HemSCs differentiate to Hem-Pericytes when injected on immunodeficient mice.  This 
differentiation was dependent on direct contact of HemSCs with cord blood endothelial 
colony-forming cells (cbECFCs) or HemECs.  Differentiation of HemSCs to Hem-
Pericytes was reduced in vivo with recombinant Jagged1 or silencing of Jagged1 in the 
cbECFCs with shRNA.  As noted above, Jagged1 binds Notch receptors.  Thus, 
Jagged1 and Notch signaling were found critical for differentiation of HemSCs to Hem-
Pericytes (Boscolo, Stewart et al.  2011). 
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Chapter II 
Treatments of infantile hemangioma 
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2.1 Therapeutic options for IH 
As noted above, IH regresses on its own over time, so some pediatricians, in 
consultation with the parents, choose not to treat it.  On the other hand, locations of IH 
in areas like eyelids and cheeks have directed some to seek treatments because of 
possible detriment to vision and likely disfigurement, respectively. 
Until recently, standard treatments of IH included laser therapy, surgical 
resection and corticosteroids.  Interferon had been reported be effective when patients 
with vision-threatening hemangiomas were treated daily for 3 months (Hastings, Milot et 
al.  1997).  However, some patients suffered from spastic diplegia, in which lower 
extremity muscles are stiffened and ambulation is reduced.  Such a severe side effect 
discouraged its adoption (Barlow, Priebe et al.  1998). 
Among the treatments for IH, surgical resection and corticosteroids have been 
utilized for decades.  As described above, location of IH in conspicuous areas like 
cheeks may motivate patients to seek consultation for removal.  Clinicians typically opt 
for surgical resection when IH is felt to have started involuting, in order to reduce the 
size of scar as much as possible.  Corticosteroids are either injected into IH and/or 
given orally, with a taper beginning after a few weeks, based on patients’ weight.  
Corticosteroids suppress VEGF-A expressed and secreted by HemSCs, which may be 
the underlying mechanism for their efficacy (Greenberger, Boscolo et al.  2010).  
Although corticosteroids have a myriad of side effects including insulin resistance and 
growth retardation, they have been widely used for a variety of conditions, in addition to 
IH, for many years.  Therefore, they had been the main non-surgical treatment option 
for IH until the adoption of propranolol.  
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Recently, rapamycin, a mTOR inhibitor, was shown to reduce proliferation and 
differentiation capability of HemSCs.  In addition, vascular volume of hemangioma 
vessels, in a murine model of IH, was reduced as a result of rapamycin treatment.   
These findings provide an intriguing possibility that it might become a treatment option 
of IH, like surgical resection, corticosteroids and propranolol (Greenberger, Yuan et al.  
2011). 
Propranolol is a non-selective β-adrenergic receptor (AR) antagonist developed 
by the British scientist James Black in the 1960s (Figure 5).  It is metabolized by liver, 
and it has been effective for treating high blood pressure and irregular heart rhythm 
because of its antagonism at β1-AR (Black, Crowther et al.  1964).  Propranolol also 
binds 5-hydroxytryptamine 1B (5-HT1B) receptors in the brain, which are involved in 
various neurological processes such as memory and learning.  In addition to its use for 
cardiac indications as listed above, propranolol has been prescribed for migraine 
prophylaxis because its activity at 5-HT1B receptors leads to vasoconstriction for relief of 
symptoms (Diener, Kaube et al.  1998; Zhelyazkova-Savova and Zhelyazkov 2003). 
 
 
 
 
Figure 5.  Molecular structure of propranolol. 
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2.2 β-ARs- an overview 
As noted above, propranolol binds β-ARs and 5-HT1B receptors.  β-ARs are more 
prevalent throughout the body than 5-HT1B receptors that are traditionally associated 
with regulatory functions in the brain.  Thus, based on their prevalence and locations, β-
ARs are likely candidates to be involved in reduction of IH by propranolol. 
  β-ARs are further subdivided into β1-, β2- and β3-ARs.  β1-AR is well-
characterized in the heart, where stimulation of the receptor by agonists such as 
epinephrine and norepinephrine leads to increases of heart rate and contractility, 
thereby increasing volume of output from the heart.  Stimulation of the receptor in 
kidneys increases secretion of renin, which is tied to vascular volume regulation and 
hence blood pressure control.  β2-AR is widely distributed throughout the body, and its 
function depends on location of the receptor.  Some effects of its stimulation by agonists 
such as epinephrine and albuterol include relaxation of airway, dilation of vessels, 
increase of glucose via glycogenolysis and gluconeogenesis and relaxation of non-
pregnant uterus.  β3-AR is well-characterized in adipose tissue and bladder, and its 
stimulation by an agonist such as Solabegron increases lipolysis and heat production in 
adipose tissue and relaxation of bladder detrusor muscle.  All β-ARs are coupled to G 
stimulatory (Gs) protein, except β2-AR, which can also be coupled to G inhibitory (Gi) 
protein (Mersmann 1998; Wallukat 2002).  The downstream effects of β1, 2-ARs 
stimulation will be described further. 
An agonist such as epinephrine will bind β1, 2-ARs, allowing Gs proteins to bind 
and activate adenylyl cyclase to increase cyclic adenosine monophosphate (cAMP).  
Four molecules of cAMP will bind regulatory subunits of protein kinase A (PKA), a  
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serine/threonine kinase, to induce a conformational change.  As a result, catalytic 
subunits of PKA are dissociated and activated, and they phosphorylate various targets 
to mediate intracellular events.  If Gi protein were to be stimulated as in the case of β2-
AR, adenylyl cyclase will be inactivated and cAMP decreased; therefore, PKA will not 
be activated.  Thus, Gs and Gi proteins mediate opposite effects. 
One action of PKA is phosphorylation and activation of phosphodiesterase, which 
converts cAMP to 5’-AMP.  By doing so, further activation of PKA by cAMP is reduced.  
Thus, PKA is downregulated by negative feedback, and its downstream effects are 
reduced. 
 
Receptor desensitization 
Pathways exist to prevent over-stimulation of β-ARs, and these have been shown in β2-
AR.  As noted above, agonist binding of β2-AR allows the coupled Gs protein to bind and 
activate adenylyl cyclase; subsequently, cAMP increases, and four molecules of cAMP 
activate PKA.  In turn, PKA phosphorylates intracellular regions of β2-AR adjacent to 
where Gs protein is coupled and change their conformation.  As a result, further 
activation of adenylyl cyclase by Gs protein is inhibited (Hausdorff, Caron et al.  1990).  
β-AR kinase, another serine/threonine kinase, has been noted to play a role in β2-AR 
desensitization, too.  It phosphorylates agonist-occupied β2-AR on its intracellular C-
terminal regions.  This allows receptor binding by β-arrestin, which in turn uncouples G 
protein from β2-AR to prevent further signaling, similar to effects of PKA phosphorylation 
noted above.  Thus, PKA, β-AR kinase and β-arrestin desensitize β2-AR to prevent its 
over-stimulation (Pippig, Andexinger et al.  1993; Wallukat 2002).  PKA phosphorylation  
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of β2-AR has also been reported to switch its coupled protein from Gs to Gi (Daaka, 
Luttrell et al.  1997).  Interestingly, β-arrestin has been reported to recruit 
phosphodiesterase to decrease cAMP, which augments its desensitization of the 
receptor, and it also participates in β-AR signaling independently of G proteins (Figure 
6; Patel, Tilley et al.  2009). 
 
 
 
 
 
Figure 6.  β2-AR signaling, desensitization and purported players. 
Adenylyl cyclase and PKA are activated as a result of catecholamine (e.g., 
epinephrine) stimulation.  PKA and G-protein receptor kinase (GRK or β-AR 
kinase in text) phosphorylate β2-AR to desensitize the receptor.  Gs switches 
to Gi upon phosphorylation by PKA.  β-arrestin uncouples Gi from β2-AR and 
recruits phosphodiesterase-4D5 (PDE4D5). 
Reproduced with permission from J Mol Cell Cardiol.  46(3):  300-8, 2009, 
Copyright Elsevier. 
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β-ARs- potential relevance in IH 
As described above, β-ARs are involved in various functions throughout the body, so 
researchers have wondered about their possible involvement in regulations of disease 
states.  Indeed, a group of researchers noted that β1, 2-ARs were expressed in 
pancreatic cancer cells.  They detected that migration of the cells was increased by 
treatment with norepinephrine, another agonist at the receptors, but propranolol 
treatment reduced such increase.  In addition, norepinephrine treatment increased 
VEGF levels of pancreatic cancer cells, but propranolol inhibited such increase, as 
detected by enzyme-linked immunosorbent assay (ELISA) and qRT-PCR (Guo, Ma et 
al.  2009).  Such an example of relationship between β-AR signaling and VEGF may be 
relevant in IH pathogenesis. 
Propranolol is a non-selective β-AR antagonist, so it will oppose actions of 
agonist at the receptors.  Therefore, in the absence of agonist, propranolol may not 
exert effects at β-ARs.  If propranolol were to exert effects at β-ARs without agonist, it 
would also be classified as an inverse agonist that, by definition, will decrease activity of 
a constitutively active receptor.  Interestingly, researchers found that propranolol could 
act as an inverse agonist at β2-AR.  They first verified β2-AR expression in rat hearts by 
Western blot and then depleted catecholamines such as epinephrine by treating rats 
with reserpine, which blocks transport of catecholamines from cytoplasm to extracellular 
membrane.  Propranolol decreased contractile force of rat heart muscles, which 
indicated its inverse agonism at β2-AR (Varma, Shen et al.  1999).  Such intriguing 
findings may have relevance in IH.  
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Another group of researchers noted that in Chinese Hamster Ovary cells 
expressing β2-AR, 10 µM of propranolol reduced basal cAMP production to 54% of 
value without stimulation by an agonist; this confirmed that propranolol is an inverse 
agonist at the receptor.  Unexpectedly, propranolol increased mitogen-activated protein 
kinase (MAPK) phosphorylation, which occurs downstream of cAMP increase and PKA 
activation, comparable to the level achieved by an agonist, isoproterenol.  These 
findings indicated that not only can propranolol act as an inverse agonist at β2-AR, but it 
can stimulate MAPK pathway independently of G proteins (Baker, Hall et al.  2003).  As 
noted above, β-arrestin could participate in β-AR signaling independently of G proteins; 
researchers found that propranolol increased MAPK phosphorylation in Human 
Embryonic Kidney 293 cells expressing β2-AR, and it promoted β-arrestin recruitment to 
β2-AR in the cells transfected with β-arrestin and β2-AR (Azzi, Charest et al.  2003).  
Therefore, activation of MAPK by propranolol could occur through β-arrestin.  In 
summary, these studies demonstrated that β-AR signaling could occur through multiple 
paths, including agonism, antagonism, inverse agonism and β-arrestin. 
 
2.3 Propranolol as an effective therapeutic for IH 
In 2008, propranolol was serendipitously discovered to be effective for treating IH.  A 
patient responded minimally to corticosteroids and developed cardiomyopathy during 
treatment.  The patient likely developed cardiomyopathy either because IH was a high-
volume lesion, causing strain to the heart, or as a side effect of corticosteroids.  The 
patient was prescribed a β-AR antagonist, propranolol, to decrease cardiac workload, 
and soon after redness and firmness of lesion decreased.  These effects were 
maintained after corticosteroids were tapered off, with continuation of propranolol only  
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(Figure 7; Léauté-Labrèze, Dumas de la Roque et al.  2008).  Although patients varied 
by gender, age, location and severity of IH, propranolol has been effective with minor 
side effects, such as nausea, diarrhea and agitation while sleeping.  Effects were seen 
as early as 24 hours after initial treatment (Sans, de la Roque et al.  2009; Lv, Fan et al.  
2012).  Clinicians noted that some patients experienced rebound in size and color after 
cessation of treatment, which prompted many to keep patients on propranolol until the 
lesion reached involuting phase (Zaher, Rasheed et al.  2011). 
 
Researchers have been interested in finding explanations behind efficacy of 
propranolol in IH, which also became my goal.  Although it is effective, patients are 
maintained on it for months, while some do not respond.  Finding how and why 
propranolol works in IH will help tailor therapies for individual patients, likely expediting 
 
 Figure 7.  Treatment with propranolol. 
A- 9 weeks of age after 4 weeks of steroids.  B- 10 weeks of age, 1 
week after propranolol treatment with steroids.  C- 6 months of age on 
propranolol monotherapy.  D- 9 months of age. 
Reproduced with permission from the N Engl J Med.  358(24):  2649-
51, 2008, Copyright  Massachusetts Medical Society. 
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recovery and improving quality of their lives.  Therefore, several groups studied this 
topic and published their findings in literature.  Initial studies were carried out with non-
pathologic human endothelial cells.  For example, propranolol was reported to decrease 
proliferation of HUVECs through a cell cycle arrest at G0/G1, with corresponding 
decreases in cyclins D1, D3 and cyclin-dependent kinase 6.  In addition, formation of 
capillary-like tubes by HDMECs was reduced, with 50% reduction of tube lengths 
occurring at ~ 37 µM (Lamy, Lachambre et al.  2010).  These findings were detected in 
the absence of agonist such as epinephrine. 
Researchers from the same group found that tube formation capability of another 
endothelial cell type, human brain microvascular endothelial cells (HBMECs), was also 
reduced, with a noticeable decrease starting at 10 µM.  However, migration and 
apoptosis of HBMECs were unaffected by propranolol concentrations up to 100 µM.  
They also noted that propranolol reduced secretion of matrix metalloproteinase 9 (MMP-
9), an enzyme involved in matrix degradation and cell migration, after treatment with a 
tumor-promoting agent phorbol 12-myristate 13-acetate  (Annabi, Lachambre et al.  
2009).  As above, propranolol exerted such effects in the absence of agonist, so 
findings by this group highlighted the possible inverse agonism of propranolol at β-ARs. 
Another group assessed the effect of propranolol on HemECs and HemSCs.  
Proliferation of HemECs and HemSCs was reduced by propranolol at 50 µM.  
Propranolol treatment of HemSCs stimulated transcription of adipogenic genes, such as 
PPARδ and RXRα, and this was verified by Oil Red O staining (Wong, Hardy et al.  
2012).  Others showed that propranolol inhibits proliferation of HemECs at 300 µM and 
also increases their apoptosis (Chim, Armijo et al.  2012; Ji, Li et al.  2012).  In  
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summary, researchers from different groups found various effects of propranolol on 
hemangioma-derived and non-hemangioma-derived cells, with and without agonist.  
Therefore, propranolol may affect a variety of cell types, in addition to hemangioma-
derived cells, by mechanisms including antagonism and inverse agonism at β-ARs. 
Some have hypothesized that propranolol exerts multiple effects to reduce IH.  
First, as a β-AR antagonist, propranolol reduces levels of cAMP, subsequently affecting 
PKA, endothelial nitric oxide synthase (eNOS) and decreasing production and release 
of nitric oxide (NO); eventually vasoconstriction occurs.  Second, as β-AR agonists 
increase pro-angiogenic factors such as VEGF and MMP-9, propranolol likely 
decreases them to oppose angiogenesis.  Third, β-AR agonists signal through Gs 
protein to increase cAMP and activate PKA; one molecule activated by PKA is Src, a 
tyrosine kinase.  Src, in turn, phosphorylates caspase-8 and inactivates it to inhibit 
apoptosis.  Therefore, authors reasoned that as a β-AR antagonist, propranolol induces 
apoptosis (Storch and Hoeger 2010).  In support of the first possibility, hemangioma 
tissues were surgically resected from patients treated or not treated with propranolol, 
and eNOS levels were shown to be decreased in tissues from patients treated with 
propranolol compared to the untreated group.  In addition, eNOS levels decreased as 
hemangiomas progressed through their 3 phases (Dai, Hou et al.  2012). 
In summary, researchers have gained leads on how and why propranolol could 
reduce IH since the initial report in 2008, but finding its mechanism remains a work in 
progress.  In the experiments described in this dissertation, HemECs and Hem-
Pericytes were affected by propranolol both in vitro and in vivo.  Therefore, they may be 
the key players, through which propranolol reduces IH. 
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2.4 Abbreviations 
5-hydroxytryptamine 1B  5-HT1B 
adrenergic receptor  AR 
alpha smooth muscle actin  αSMA 
basic fibroblast growth factor  bFGF 
bone marrow mesenchymal progenitor cells  bmMPCs 
cyclic adenosine monophosphate  cAMP 
cord blood endothelial colony-forming cells  cbECFCs 
diaminobenzidine  DAB 
diacylglycerol  DAG 
4', 6-diamidino-2-phenylindole  DAPI 
Dulbecco’s Modified Eagle Medium  DMEM 
Endothelial Basal Medium-2  EBM-2 
epidermal growth factor  EGF 
Endothelial Growth Medium-2  EGM-2 
enzyme-linked immunosorbent assay  ELISA 
endothelial nitric oxide synthase  eNOS 
extracellular signal-regulated kinases 1/2  ERK 1/2 
fetal bovine serum  FBS 
glyceraldehyde 3-phosphate dehydrogenase  GAPDH 
glucose transporter-1  GLUT1 
human brain microvascular endothelial cells  HBMECs 
human dermal microvascular endothelial cells  HDMECs 
hematoxylin & eosin  H & E 
hemangioma-derived endothelial cells  HemECs 
hemangioma-derived pericytes  Hem-Pericytes 
hemangioma-derived stem cells  HemSCs 
hypoxia-inducible factor 1α  HIF1α 
heparan sulfate proteoglycan  HSPG 
human umbilical vein endothelial cells  HUVECs 
hypoxanthine phosphoribosyltransferase 1  HPRT1 
immunofluorescence  IF 
infantile hemangioma  IH 
immunohistochemistry  IHC 
interferon-β  IFN-β 
inositol 1, 4, 5-trisphosphate  IP3 
mitogen-activated protein kinases  MAPK 
mammalian target of rapamycin  mTOR 
matrix metalloproteinase 9  MMP-9 
microvessel density  MVD 
nuclear factor of activated T cells  NFAT 
nuclear factor-kB  NF-kB 
neural glial antigen-2  NG2 
Notch intracellular domain  NICD  
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2.4 Abbreviations (continued) 
nitric oxide  NO 
neuropilin  NRP 
phosphate buffered saline  PBS 
platelet-derived growth factor receptor β  PDGFR-β 
polydimethylsiloxane  PDMS 
phosphoinositide 3-kinase  PI 3-kinase 
phosphatidylinositol 4,5-bisphosphate  PIP2 
protein kinase A  PKA 
protein kinase C  PKC 
phospholipase C  PLC 
placental growth factor  PlGF 
quantitative real time polymerase chain reaction  qRT-PCR 
red blood cell  RBC 
smooth muscle cells  SMCs 
smooth muscle myosin heavy chain  smMHC 
tumor endothelial marker-8  TEM8 
urokinase plasminogen activator receptor  uPAR 
vascular endothelial growth factor A  VEGF-A 
vascular endothelial growth factor B  VEGF-B 
vascular endothelial growth factor receptor-1  VEGFR1 
vascular endothelial growth factor receptor-2  VEGFR2 
vascular endothelial growth factor receptor-3  VEGFR3 
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Chapter III 
Confirming the presence of known targets of propranolol in IH 
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3.1 Preliminary studies 
Since its discovery as an effective therapeutic for IH in 2008, propranolol has been 
widely adopted in medical centers around the world (Sans, de la Roque et al.  2009).  
Patients respond differently to various medications, so clinicians need to tailor 
appropriate therapies for patients.  In order to design individualized therapies for 
patients, it will be important to clarify mechanism of propranolol in IH. 
As described above, several experimental results have been reported.  Some 
showed that propranolol inhibits proliferation of HemECs at 300 µM and also increases 
their apoptosis (Chim, Armijo et al.  2012; Ji, Li et al.  2012).  Another group showed 
that propranolol inhibits tube formation of brain endothelial cells (Annabi, Lachambre et 
al.  2009).  These results suggested that propranolol might block angiogenic activities of 
endothelial cells. 
Shoshana Greenberger, a former Bischoff Laboratory member, was interested in 
finding out the effects of propranolol on hemangioma-derived cells.  She observed that 
propranolol treatment did not affect RNA or protein levels of VEGF-A in HemSCs, part 
of which I confirmed by qRT-PCR in other HemSCs.  She also treated HemECs and 
HemSCs with propranolol for 48 hours.  She took the conditioned media and tested 
them for simultaneous detection of 43 proteins commonly associated with angiogenesis, 
obtained from protein array kits.  However, no significant changes were detected with 
propranolol treatment (not shown). 
In her studies, proliferation of HemSCs and differentiation of HemSCs to ECs or 
HemSCs to smooth muscle cells were not affected by propranolol treatment (not 
shown).  
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A note on the molarity of propranolol chosen for in vitro studies 
As described above, effects of propranolol on hemangioma- and non-hemangioma-
derived cells have been noted by other researchers at 10-300 µM.  Its half life is 3-5 
hours, and the binding affinities of propranolol for β1- and β2-ARs are 2.8 nM and 0.62 
nM (Ki), respectively (Pauwels, Gommeren et al.  1988).  Clinicians prescribe 1-5 mg/kg 
per day for patients, and its plasma concentrations after 1 mg/kg treatments were 
reported to range from 0 to 1.4 µM (Sans, de la Roque et al.  2009; Lv, Fan et al.  2012; 
Zhang, Mai et al.  2013).  A concentration of 10 µM was chosen for in vitro experiments 
based on literature reports and to avoid adding vastly excessive amounts of drug.  
Propranolol was also added twice daily for in vitro assays lasting days because of its 
half life. 
 
3.2 Tube formation of HemECs and HemSCs not affected by propranolol 
As noted above, researchers found that tube formation capability of normal endothelial 
cells such as HDMECs was reduced, with 50% reduction of tube lengths occurring at ~ 
37 µM of propranolol (Lamy, Lachambre et al.  2010).  They found that tube formation 
capability of HBMECs was also reduced, with a noticeable decrease starting at 10 µM of 
propranolol (Annabi, Lachambre et al.  2009).  Consequently, it was of interest to find 
out whether tube formation capability of hemangioma-derived cells would be affected by 
propranolol treatment. 
In addition to HemECs, HemSCs have been noted to form tubes on a thin layer 
of Matrigel.  This indicated their possession of endothelial-cell-like properties, on top of 
their stem cell traits, even before their differentiation to HemECs (Boscolo, Mulliken et  
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al.  2011).  Therefore, HemECs and HemSCs were tested in tube formation assays.  
Hem-Pericytes were not assayed. 
HemECs, HemSCs and HDMECs were tested in tube formation assay, with 
HDMECs as a positive control cell type (Figure 8).  For each type, cells were either 
treated with vehicle or propranolol once.  As shown in Figure 8, no noticeable 
differences were detected in the tubes formed by vehicle- and propranolol-treated 
HemECs, HemSCs and HDMECs after 18 hours.  Pictures are representative of 
multiple experiments on 2 different HemECs (133 and I-69) and 5 different HemSCs 
(125, 129, 133, 140 and I-54).  
 
As noted above, researchers reported that propranolol decreased tube formation 
of HBMECs and HDMECs.  Their experiments were conducted without an agonist such 
 
 
Figure 8.  Tube formation assays of HemECs, HemSCs and HDMECs. 
Cells were treated once with vehicle or propranolol.  Pictures are 
representative of images from 4 wells and multiple experiments. 
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as epinephrine.  Therefore, propranolol might have acted on targets other than β-ARs or 
as inverse agonists to decrease tube formation.  Tube formation assays in Figure 8 
could have been performed more comprehensively, for example by taking 
measurements of tube lengths, adding epinephrine on top of propranolol or adding an 
inhibitor (e.g., Avastin) and assessing whether or not propranolol duplicates the effects 
of the inhibitor.  Given the negative results from Figure 8 and high degrees of variability 
and subjectivity of tube formation assays, such steps were not taken. 
 
3.3 Assessing for presence of 5-HT1B receptors in IH 
After such negative results, it was decided that confirming the presence of known 
receptors of propranolol, 5-HT1B and β-ARs, in IH might be a good starting point.  They 
are known targets of the drug, so their presence may indicate drug binding to lead to 
further actions.  Presence of 5-HT1B receptor in IH tissue was assessed by 
immunofluorescence (IF), and human brain tissue used as a positive control (Figure 9). 
 
 
 
Figure 9.  Immunostaining for 5-HT1B receptor in brain and IH tissue. 
The receptor was visualized by utilizing Alexa Fluor 488 as the secondary.  
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RNA levels of 5-HT1B receptor in HemECs and Hem-Pericytes were assessed, with 
bone marrow mesenchymal progenitor cells (bmMPCs) as a positive control (Figure 10). 
 
5-HT1B receptor was not detected in IH by IHC (Figure 9), but low levels of the receptor 
were detected in Hem-Pericytes 146 by qRT-PCR (Figure 10).  However, only few 
samples of hemangioma-derived cells, one each of HemECs and Hem-Pericytes, were 
used in qRT-PCR, and bmMPCs might not be a good positive control for 5-HT1B 
receptor.  Rather, a better control might be brain cells known to be involved in 
serotonergic neurotransmission.  Although cDNA samples of cells were loaded into 
triplicate wells for qRT-PCR, these provided technical replicates for pipetting accuracy; 
cells were grown and harvested from single plates, from which RNA extracted and 
cDNA reverse-transcribed.  As they were not grown in multiple wells or plates, no error 
bars could be added to the graph in Figure 10. 
In summary, 5-HT1B receptor was not detected by IHC with a good positive 
control, and very little was detected in two hemangioma-derived cell types by qRT-PCR.  
Therefore, receptor expression was low in IH, and from this point on, the focus shifted to 
 
 Figure 10.  RNA levels of 5-HT1B receptor. 
Ratios of 5-HT1B/GAPDH in hemangioma-derived cells 
were re-normalized to that of bmMPCs, set to 1.  
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confirming presence of adrenergic receptors in IH.  Adrenergic receptors are widely 
expressed throughout the body, whereas 5-HT1B receptors are more highly-associated 
with the nervous system.  Based on this fact, adrenergic receptors are more likely to be 
expressed than 5-HT1B receptors in IH. 
 
3.4 IHC studies of α1b- and β2-ARs in IH 
Propranolol binds β-ARs, so presence of adrenergic receptors was assessed in IH 
tissues by IHC.  Human brain tissue expresses both 5-HT1B and adrenergic receptors, 
so it was used as a positive control again.  Presence of α1b-AR was assessed in 
addition to β2-AR because epinephrine, agonist at β-ARs, may exert effects at α1b-AR if 
β-ARs are bound by propranolol.  Immunostaining for α1b-AR hinted at expression by 
endothelial cells in one IH tissue (IH #1; Figure 11), whereas expression was more 
difficult to detect in another (IH #2; Figure 11). 
 
 
 Figure 11.  Immunostaining for α1b-AR in brain and IH tissues. 
The receptor was visualized by utilizing horse radish peroxidase as the 
secondary.  IH #1 showed potential expression by endothelial cells, but 
expression was more difficult to detect in IH #2.  
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Immunostaining for β2-AR hinted at expression by endothelial and some stromal cells in 
two tissues (IH #1, Ab #1; IH #2, Ab #1; Figure 12).  However, immunostaining in the 
same tissues with another commercially available antibody showed expression not by 
hemangioma vessels or stroma but by sweat glands and mast cells, respectively (IH #1, 
Ab #2; IH #2, Ab #2; Figure 12).  These findings were confirmed by a review with Dr. 
Harry Kozakewich, a pathologist at Boston Children’s Hospital. 
 
 
 Figure 12.  Immunostaining for β2-AR in brain and IH tissues. 
The receptor was visualized by utilizing horse radish peroxidase as the 
secondary.  Ab #1 in IHs #1 & #2 hinted at expression by endothelial and 
some stromal cells, but Ab #2 in IH #1 showed expression by sweat 
glands.  Ab #2 in IH #2 showed expression by mast cells. 
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In summary, even though immunohistochemistry (IHC) with adrenergic receptor 
antibodies was performed on select hemangioma tissues, patterns of staining were 
inconsistent from tissue to tissue for both α1b- and β2-ARs.  This might have been 
reflective of variability of ARs expression levels from tissue to tissue, and mast cells 
have been described in literature to express β2-AR (Johnson 2002).  However, the 
different results from 2 antibodies for β2-AR on the same tissues were concerning (IH 
#1, Ab #1 vs. IH #1, Ab #2; IH #2, Ab #1 vs. IH #2, Ab #2; Figure 12).  These 
phenomena might be attributed to factors such as quality of the antibodies and the 
difficulty of antibody-labeling adrenergic receptors that are highly embedded in the 
plasma membrane with 7-transmembrane spanning domains. 
On the other hand, a group of researchers used a tissue microarray that 
contained various vascular anomalies, including IH, and immunostained for β2, 3-ARs 
and phosphorylated form of β2-AR.  They found that all 3 phases of IH expressed all 3 
receptors tested, except that the proliferating phase expressed phosphorylated form of 
β2-AR weakly.  Although no isotype-matched or positive controls were shown, a variety 
of vascular anomalies were tested for comparison (Chisholm, Chang et al.  2012).  Even 
though the reasons behind their success may be multifactorial, they used different 
antibodies from the ones used in Figure 12. 
 
3.5 RNA levels of β1, 2-ARs in IH tissues 
As described above, in the attempts to detect ARs in IH by IHC, inconsistent results 
were noted from one IH tissue to another and from one antibody to another.  At the 
recommendation of dissertation advisory committee, it was decided to utilize qRT-PCR  
45 
 
to detect RNA levels of ARs in IH tissues.  By doing so, the expectation was to avoid 
potential problems with quality of the antibodies and the difficulty of antibody-labeling 
adrenergic receptors.  Hemangioma tissues from patients of various ages, from 3 
months to 10 years of age, were chosen, and their RNA isolated as described in 
Methods.  Receptors assayed include β1-3- and α1b-ARs (Figure 13).  For each receptor, 
expression level was normalized to β-actin, a reference gene chosen because it was 
expressed in all hemangioma tissues tested.  This was in contrast to other reference 
genes like glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and hypoxanthine 
phosphoribosyltransferase 1 (HPRT1); some tissues did not even express GAPDH or 
HPRT1.  β-actin might have been a good reference gene in this case because it is a 
structural gene, whereas GAPDH and HPRT1 are metabolic genes.  Structural genes 
may be better than metabolic genes to serve as reference genes for surgically resected 
tissues, whereas it may be the other way around for cultured cells. 
The level of expression of AR/β-actin was re-normalized to AR expression in a 
positive control tissue/cell type normalized to β-actin in the same control, set to 1.  For 
example, β1-AR/β-actin of tissues was normalized to β1-AR/β-actin in cardiac tissue 
which was set to 1, whereas β2-AR/β-actin of tissues was to β2-AR/β-actin in bladder 
SMCs which was also set to 1.  Expression levels of β3- and α1b-ARs among 
hemangioma tissues varied from patient-to-patient and were generally low compared to 
their positive controls (Figure 13C, D).  However, β1, 2-ARs were consistently detected in 
most hemangioma specimens, except those from ages 15 and 21 months, and levels 
were more remarkable for β2- than β1-AR. (Figure 13A, B).  
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Figure 13.  β1, 2-adrenergic receptors are highly expressed across 
hemangioma tissues. 
RNA was extracted from hemangioma tissues resected from patients of different 
ages, and qRT-PCR performed as described in Methods.  Samples were run in 
triplicates, and the entire analysis was repeated once.  Copy numbers for 
adrenergic receptors and β-actin were obtained by the standard curve method.  
Each qRT-PCR included HUVECs and a positive control tissue/cell type (cardiac 
tissue for β1 in A, bladder SMCs for β2 in B, foreskin for β3 in C and bronchial SMCs 
for α1b in D), to which values of adrenergic receptor/β-actin were normalized.  
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RNA levels of β1, 2-ARs in IH tissues:  significance & caveats 
Expression of β1, 2-ARs in IH tissues was easily appreciated in IH tissues.  To date, RNA 
expression of β-ARs has been frequently reported in hemangioma-derived cells, but not 
in IH tissues (Wong, Hardy et al.  2012; Rössler, Haubold et al.  2013).  In addition, IH 
tissues from different ages and patients are represented, providing a spectrum of 
information. 
  In order to examine RNA levels of β2-AR in IH tissues more closely, RNA levels 
of β2-AR to CD31 (Figure 14A) and to αSMA (Figure 14B) for each tissue were 
obtained.  IH has abundances of endothelial cells and pericytes; therefore, RNA levels 
of β2-AR were normalized to markers of endothelial, CD31, and pericytic, αSMA, cells.  
RNA levels of β2-AR were more remarkable if they were normalized to CD31 compared 
to αSMA.  In order to get an idea of endothelial cell contents of tissues, RNA levels of 
CD31 to β-actin were derived (Figure 14C).  In contrast to what was done for IH tissues, 
these quotients from Figure 13 were not re-normalized to those of positive controls, 
which were HUVECs for β2/CD31 (Figure 14A), bladder SMCs for β2/αSMA (Figure 
14B) and HUVECs again for CD31/β-actin (Figure 14C).  Although the tissues varied 
widely in their relative endothelial cell contents to β-actin, it was affirming to see that all 
tissues had endothelial cells, especially ones that did not express ARs, from ages 15 
and 21 months.  Expression levels of ARs might be heterogeneous in a tissue, and 
parts low in receptors might have been used to isolate RNA, which could explain why 
samples from ages 15 and 21 months did not express ARs. 
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  Different positive controls were used for each adrenergic receptor- cardiac tissue 
for β1-AR, bladder SMCs for β2-AR, foreskin for β3-AR and bronchial SMCs for α1b-AR.  
Such measures were necessary because, unfortunately, no one positive control 
expressed high levels of all 4 ARs assayed.  In addition, each time point (e.g., 3 
months) had tissue from one patient, so variability of AR expression among multiple 
patients at the same time point could not be assessed.  Although cDNA samples of 
tissues were loaded into triplicate wells for qRT-PCR, these provided technical, not 
tissue, replicates; hence no error bars could be added to Figures 13 and 14. 
 
Figure 14.  RNA levels of β2-AR in IH tissues normalized to different 
genes and endothelial cell contents of IH tissues. 
RNA levels of β2-AR were normalized to CD31 in A and αSMA in B.  CD31 
levels of IH tissues were normalized to β-actin in C. 
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  Unfortunately, β2-AR detection in bladder SMC, a positive control, by Western 
blot with the two β2-AR antibodies from Figure 12 was not successful (not shown), so no 
attempts were made with IH tissues.  Expression of β1-AR in IH tissues was not 
assessed by Western blot or IHC.  Micro RNAs could have reduced RNA levels of β1, 2-
ARs, thereby resulting in lower protein levels of β1, 2-ARs than one might have expected 
from RNA levels.  However, given that β1, 2-ARs were expressed across many IH 
tissues, this possibility was not likely to have occurred consistently in the samples. 
 
3.6 RNA levels of β1, 2-ARs in hemangioma-derived cells 
After finding that β1, 2-ARs were consistently expressed in most hemangioma tissues, 
their expression levels in specific populations of hemangioma-derived cells were 
assessed.  Several reference genes, β-actin, GAPDH, HPRT1 and S9, were tested, and 
the standard curve method was utilized to generate copy numbers of the reference 
genes for samples. 
Table 1.  Copy numbers of β-actin among hemangioma-derived cells & controls. 
ECs 
17 
ECs 
20 
ECs 
21 
ECs 
125 
ECs 
133 
ECs 
150 
ECs  
I-69 
Peric
-ytes 
146 
Peric
-ytes 
157 
Peric
-ytes 
I-69 
SCs 
97 
SCs 
120 
SCs 
125 
37  91  65  22  50  40  68  67  28  16  81  46  66 
 
SCs 
128 
SCs 
129 
SCs 
133 
SCs 
140 
SCs 
 I-54 
Bladder 
SMCs 
Cardiac 
tissue 
52  118  114  75  80  36  1 
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Table 2.  Copy numbers of GAPDH among hemangioma-derived cells & controls. 
ECs 
17 
ECs 
20 
ECs 
21 
ECs 
125 
ECs 
133 
ECs 
150 
ECs  
I-69 
Peric
-ytes 
146 
Peric
-ytes 
157 
Peric
-ytes 
I-69 
SCs 
97 
SCs 
120 
SCs 
125 
21  51  54  36  71  45  94  72  19  21  55  56  67 
 
SCs 
128 
SCs 
129 
SCs 
133 
SCs 
140 
SCs 
 I-54 
Bladder 
SMCs 
Cardiac 
tissue 
53  62  47  48  49  25  4 
 
Table 3.  Copy numbers of HPRT1 among hemangioma-derived cells & controls. 
ECs 
17 
ECs 
20 
ECs 
21 
ECs 
125 
ECs 
133 
ECs 
150 
ECs  
I-69 
Peric
-ytes 
146 
Peric
-ytes 
157 
Peric
-ytes 
I-69 
SCs 
97 
SCs 
120 
SCs 
125 
267  291  245  132  326  74  345  132  45  34  144  146  148 
 
SCs 
128 
SCs 
129 
SCs 
133 
SCs 
140 
SCs 
 I-54 
Bladder 
SMCs 
Cardiac 
tissue 
98  247  276  122  123  39  39 
 
Table 4.  Copy numbers of S9 among hemangioma-derived cells & controls. 
ECs 
17 
ECs 
20 
ECs 
21 
ECs 
125 
ECs 
133 
ECs 
150 
ECs  
I-69 
Peric
-ytes 
146 
Peric
-ytes 
157 
Peric
-ytes 
I-69 
SCs 
97 
SCs 
120 
SCs 
125 
145  87  174  34  178  82  309  144  24  4  77  44  100 
 
SCs 
128 
SCs 
129 
SCs 
133 
SCs 
140 
SCs 
 I-54 
Bladder 
SMCs 
Cardiac 
tissue 
41  52  88  70  59  77  12 
 
All samples expressed the 4 reference genes, and GAPDH was chosen because its 
copy numbers varied the least among the cells.  As noted above, a different reference 
gene, β-actin, was used for hemangioma tissues.  Like what was done for hemangioma 
tissues, expression levels of β1, 2-AR/GAPDH were re-normalized to AR expression in a 
positive control tissue/cell type normalized to GAPDH in the same control, set to 1.   
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Expression of β1-AR was noted in all HemECs, but not in most Hem-Pericytes and 
HemSCs (Figure 15A).  Expression of β2-AR was detected in all three cell types, but the 
highest and most consistent expression occurred in HemECs (Figure 15B). 
 
 
 
Figure 15.  β1, 2-ARs levels in hemangioma-derived cells. 
A.  β1-AR expression relative to GAPDH, normalized to cardiac tissue. 
B.  β2-AR expression relative to GAPDH, normalized to bladder SMCs.  
Four reference genes, β-actin, GAPDH, HPRT1 and S9, were tested, 
and GAPDH was chosen because its expression varied the least 
among the samples.  Please refer to Tables 1-4 for copy numbers.  
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RNA levels of β1, 2-ARs in hemangioma-derived cells:  significance & caveats 
RNA levels of β1, 2-ARs in hemangioma-derived cells have been reported in literature 
(Wong, Hardy et al.  2012; Rössler, Haubold et al.  2013).  In Figure 15, hemangioma-
derived cells from different patients are represented, providing a wide spectrum of 
information. 
Different positive controls were used for each adrenergic receptor- cardiac tissue 
for β1-AR and bladder SMCs for β2-AR.  This was necessary because neither expressed 
high levels of both β1, 2-ARs.  Although β1, 2-ARs were expressed in both IH tissues and 
hemangioma-derived cells, expression levels were higher in tissues.  This might be a 
result of change in levels of β1, 2-ARs brought on by cell culture.  However, 
hemangioma-derived cells in culture have been noted to retain characteristics they 
show in vivo.  For instance, endothelial cell markers such as angiopoietin-2, E-selectin 
and Jagged1 were expressed by IH tissues and HemECs in culture (Calicchio, Collins 
et al.  2009; Kräling, Razon et al.  1996; Yu, Varughese et al.  2001; Smadja, Mulliken et 
al.  2012; Boscolo, Stewart et al.  2011).  Likewise, pericytic markers such as αSMA, 
calponin, NG2 and PDGFR were expressed by IH tissues and Hem-Pericytes in culture 
(Boscolo, Stewart et al.  2011; Boscolo, Mulliken et al.  2013). 
As noted above, cDNA samples of cells were loaded into triplicate wells for qRT-
PCR, and these provided technical replicates.  Cells were grown and harvested from 
single plates, from which RNA extracted and cDNA reverse-transcribed.  As they were 
not grown in multiple wells or plates, no error bars could be added to the graphs in 
Figure 15.  Nevertheless, Figure 15 contained cells from multiple patients for each  
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hemangioma-derived cell type, so a statistical analysis of data was made feasible in 
Figure 16. 
 
  Although the attempts to detect ARs in IH tissues by IHC and Western blot 
yielded inconsistent and unsuccessful results, ARs were consistently detected in 
hemangioma-derived cells by qRT-PCR.  Given that β-ARs were expressed consistently 
across many hemangioma-derived cells, one can deduct the location of β-ARs in IH 
tissues, on endothelial cells for β1-AR and on endothelial, pericytic and stem cells for β2-
AR. 
 
 
 
 
Figure 16.  β1, 2-ARs levels by hemangioma-derived cell types. 
A.  β1-AR expression relative to GAPDH, normalized to cardiac tissue, for 
each cell type.  The differences in receptor levels were significant for 
HemECs-HemSCs.  Only 1 out of 3 Hem-Pericytes expressed β1-AR, so 
further statistical analysis was not done. 
B.  β2-AR expression relative to GAPDH, normalized to bladder SMCs, for 
each cell type.  The differences in receptor levels were significant for the 
following pairs: HemECs-HemSCs and Hem-Pericytes-HemSCs.  The 
differences were not significant for HemECs-Hem-Pericytes. 
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Chapter IV 
Hemangioma-derived cell types affected by propranolol 
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4.1 Effect of propranolol on hemangioma-derived cells 
After much trial-and-error, the presence of known targets of propranolol, β-ARs, was 
confirmed in IH.  From this point on, potential importance of β-ARs, in the efficacy of 
propranolol in IH, was studied.  Experimental results from this section indicated that 
propranolol affects proliferation of HemECs and Hem-Pericytes and contractility of Hem-
Pericytes. 
 
4.2 Propranolol reduces proliferation of HemECs and pericytes 
As described above, some researchers showed that propranolol inhibits proliferation of 
HemECs at 300 µM; while others noted that proliferation of HemECs and HemSCs was 
reduced by propranolol at 50 µM (Chim, Armijo et al.  2012; Wong, Hardy et al.  2012).  
The Bischoff Laboratory has an extensive set of hemangioma-derived cells, so effect of 
propranolol on proliferation of hemangioma-derived cells was assessed. 
Proliferation of hemangioma-derived cells was tested after treating with either 
phosphate buffered saline (PBS) or propranolol twice daily over a 5-day period.  
Proliferation assays were performed on HemECs (n = 4), Hem-Pericytes (n = 3) and 
HemSCs (n = 3).  Results for HemSCs 133, HemECs 158 and HDMECs are shown in 
Figure 17A, whereas Hem-Pericytes 154 and non-hemangioma pericytes are shown in 
Figure 17B.  Each isolate was from a different IH from a different patient.  Error bars are 
based on counts from 4 different wells.  
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As described above, RNA expression of β-ARs in IH tissues and hemangioma-derived 
cells was noticeable, so it was assessed whether the receptors contributed towards 
cellular proliferation.  Four separate plates of Hem-Pericytes 154 were transfected with 
non-targeting, β1-, β2- or β1+2-ARs siRNAs, and their proliferation rates in response to 
PBS or propranolol treatment were determined.  Non-targeting siRNA treatment had no 
effect on proliferation of Hem-Pericytes 154 treated with PBS over 5 days (white bars 
 
Figure 17.  Proliferation of hemangioma-derived and non-hemangioma-
derived cells in response to PBS or propranolol. 
A.  Propranolol did not reduce proliferation of HemSCs 133 and HDMECs but 
reduced proliferation of HemECs 158.  B.  Propranolol reduced proliferation of 
Hem-Pericytes 154 & human placental and retinal pericytes.  C.  Propranolol 
reduced proliferation of Hem-Pericytes 154 transfected with β-ARs siRNAs. 
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for Day 5 in Figure 17B and 17C).  On the other hand, β-ARs siRNAs transfection 
reduced proliferation compared to non-targeting siRNA among PBS-treated cells:  β1-
AR by 54%, β2-AR by 35% and β1+2-ARs by 52% (white bars relative to non-targeting 
siRNA on Day 5 in Figure 17C).  Propranolol further reduced proliferation in Hem-
Pericytes 154 transfected with β1-, β2- and β1+2-ARs siRNAs (gray bars in Figure 17C).  
siRNA knockdown efficiencies are shown in Figure 18.  Off-target effects of non-
targeting siRNA might have affected β-ARs levels, but unfortunately they were not 
assessed.  Hem-Pericytes 154 should have been transfected with no siRNA, non-
targeting siRNA, β1-, β2- and β1+2-ARs siRNAs. 
 
β-ARs siRNAs transfection was not performed in HemECs, so this should be done in 
the future. 
 
 
 
Figure 18.  β1,2-ARs knockdown efficiencies in Hem-Pericytes 154. 
A.  β1-AR/GAPDH levels in pericytes transfected with β1- and β1+2-ARs 
siRNAs relative to non-targeting siRNA. 
B.  β2-AR/GAPDH levels in pericytes transfected with β2- and β1+2-ARs 
siRNAs relative to non-targeting siRNA. 
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Proliferation assays:  significance & caveats 
Propranolol has been reported to affect proliferation of HemECs at 300 µM (Chim, 
Armijo et al.  2012; Ji, Li et al.  2012).  In Figure 17, propranolol reduced proliferation of 
HemECs and Hem-Pericytes at 10 µM, without significantly affecting HemSCs.  
Numbers from proliferation assays for each cell type are provided below to supplement 
Figure 17. 
 
Table 5.  Cell numbers on Day 5. 
HemECs  Average cell # on 
Day 5- PBS 
Average cell # on 
Day 5- propranolol 
Percent  
reduction 
133  57,100  56,600  0.9 
150  6,465  4,350  32.7 
158  19,465  10,865  44.2 
I-69  37,850  25,100  33.7 
 
Hem-
Pericytes 
Average cell # on 
Day 5- PBS 
Average cell # on 
Day 5- propranolol 
Percent 
reduction 
146  16,100  10,220  36.5 
154  10,800  5,533  48.8 
156  9,580  5,925  38.2 
 
HemSCs  Average cell # on 
Day 5- PBS 
Average cell # on 
Day 5- propranolol 
Percent 
reduction 
94  15,490  12,907  16.7 
97  112,200  112,400  - 
133  32,590  26,130  19.8 
 
  Average cell # on 
Day 5- PBS 
Average cell # on 
Day 5- propranolol 
Percent 
reduction 
HDMECs  23,440  21,780  7.1 
Placental 
pericytes 
6,455  3,330  48.4 
Retinal 
pericytes 
9,465  3,905  58.7 
 
Into each well of 48-well plates, 3750 cells were seeded (density of 5000 cells/cm
2), and 
Table 5 lists cells whose numbers at least doubled by Day 5.  The different proliferation  
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rates within and among cell types can be easily appreciated.  The differences in rates 
might have occurred because cells were derived from tissues, resected from different 
patients, at different ages and different points along the natural course of IH. 
As noted above, proliferation of HemECs was reduced by propranolol, but not 
that of a non-pathologic endothelial cell type, HDMECs.  On the other hand, proliferation 
of Hem-Pericytes and non-hemangioma pericytes, from human placenta and retina, was 
reduced by propranolol treatment, which indicates that the anti-proliferative effect of 
propranolol is not restricted to Hem-Pericytes.  Another point of interest is reduction of 
proliferation in Hem-Pericytes transfected with β1-, β2- and β1, 2-ARs siRNAs.  The 
striking decrease in proliferation strongly suggests that β-AR contributes to the 
proliferative capacity of Hem-Pericytes.  In these transfected cells, propranolol 
treatment nearly abolished proliferation over the 5 days. 
As described in Methods, HemECs were grown in media supplemented with 20% 
fetal bovine serum (FBS) and growth factors, whereas Hem-Pericytes were in media 
with 10% FBS without growth factors.  Parameters such as percentage of serum and 
presence of growth factors could have been modified to assess proliferation more 
extensively.  In addition, 10 µM of propranolol was used in proliferation assays, which 
was much greater than the binding affinities of propranolol at β1, 2-ARs. 
Another caveat is that cells were treated either with PBS or propranolol designed 
for intravenous administration in patients.  Ideally, a vehicle that closely resembled 
propranolol should have been used instead of PBS, but the vehicle, provided by Boston 
Children’s Hospital Pharmacy, was not available when proliferation assays had been 
conducted.  The dilution factor was 1 in 340 for PBS and propranolol.  
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Finally, no agonists, such as epinephrine, were used with propranolol.  As an 
antagonist at β-ARs, propranolol by itself may not exert effects at the receptors.  
Nevertheless, proliferation of HemECs and Hem-Pericytes was reduced by propranolol 
alone.  One possibility is that propranolol might have acted on targets other than β-ARs, 
but phosphorylation status of β-ARs and levels of downstream molecules such as cAMP 
were not assessed; whether propranolol bound β-ARs to decrease cellular proliferation 
or not could not be ascertained.  Another possibility is that propranolol acted as an 
inverse agonist at β-ARs. 
Propranolol reduced proliferation of HemECs and Hem-Pericytes over the 5 
days, but no effects were noted on Day 2, even though proliferation rates varied widely 
among cells (not shown).  As described above, patients often experienced changes in 
color and size of IH as early as 24 hours after initial treatment.  Given this discrepancy, 
reduction of cellular proliferation may be a reason for long-term efficacy of propranolol in 
IH, but not for immediate efficacy within 24 hours of administration. 
 
4.3 Cellular contractility assessment as a functional assay. 
β1, 2-ARs were detected in hemangioma-derived cells, and it was of interest to find out 
whether these receptors served specific functions in IH.  Patients treated with 
propranolol experienced decrease in lesion firmness and redness often within 24 hours, 
so vascular volume reduction was postulated to be a reason for the efficacy of drug.  If 
propranolol is able to contract hemangioma-derived cells, vascular volume in 
hemangioma vessels may be reduced.  Cellular contractility has been well-described in 
literature, especially that of bovine retinal pericytes (BRPs).  Percentage of serum was  
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found to directly correlate with cellular contractility (Kelley, D’Amore et al.  1987).  It was 
of interest to see if a similar set-up could be applied to hemangioma-derived cells. 
  After discussing this possibility with my supervisor Dr. Joyce Bischoff, she set up 
a meeting with Dr. Ira Herman from Tufts.  After learning how to perform contractility 
assays, baseline contractility of hemangioma-derived and non-hemangioma-derived 
cells was assessed and compared among one another (Figure 19). 
 
Among the 3 hemangioma-derived cell types, HemECs and HemSCs exhibited low 
contractility, with fewer than 5% of cells contracting on PDMS.  Contractility of HDMECs 
and Hem-Pericytes was about even, with 10-50% of cells contracting at any given time.  
BRPs exhibited the highest amount of contractility, with 50-100% of cells contracting.  
 
 
Figure 19.  Hemangioma-derived cells, HDMECs and BRPs on polydimethyl-
siloxane (PDMS). 
Cells were seeded on PDMS as described in Methods.  Two % serum was used for 
the 5 cell types in order to avoid excessive contractility.  Pictures are representative 
of multiple wells.  The picture of Hem-Pericytes was taken near a “mark,” designed 
to facilitate cell-locating after treatment.    
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Therefore, Hem-Pericytes were the most contractile on PDMS among hemangioma-
derived cells.  This was intriguing because pericytes surround small vessels, contract or 
relax to change vessel diameters and therefore, regulate vascular volume (Peppiatt, 
Howarth et al.  2006; Yemisci, Gursoy-Ozdemir et al.  2009).  After low contractility of 
HemECs 133, 150, 158 and I-69 and HemSCs 94 and 133 was noted, contractility 
assays were performed on Hem-Pericytes as described in 4.4. 
 
4.4 Hem-Pericytes and contractility assay 
As noted above, HemECs and HemSCs did not contract or “wrinkle” the PDMS as 
readily as Hem-Pericytes, so contractility assays were performed on Hem-Pericytes 
isolated from different IH tumor specimens (Figure 20B).  Elisa Boscolo, a Bischoff 
Laboratory member, isolated Hem-Pericytes from proliferating and involuting phases.  
She assessed expression of β2-AR among these cells and generously provided them, 
enabling contractility assays to proceed.  In her studies, Hem-Pericytes 146 and 154 
expressed β2-AR at relatively high levels compared to other Hem-Pericytes (not shown). 
  Hem-Pericytes 146 and 154 exhibited relaxation of wrinkles upon treatment with 
the agonist, epinephrine (dark gray bar), but addition of propranolol (light gray bar) 
blocked this relaxation (Figure 20A, left column).  The same phenomena were not 
observed in human placental and retinal pericytes, Hem-Pericytes 156, and Hem-
Pericytes from involuting phase of IH, which are I-69, I-79 and I-82 (Figure 20A, left 
column).  Among Hem-Pericytes from involuting phase, β2-AR expression levels (not 
shown) did not correspond to whether cells exhibited relaxation or inhibition upon 
treatment with epinephrine and propranolol.  
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Figure 20.  Contractility assays of Hem-Pericytes. 
A.  Quantification of data from 6 Hem-Pericytes, 3 each from proliferating and 
involuting phases, are shown.  The 4 different colors represent the 4 different 
treatments.  The height of each bar is percentage of contractility of cells to pre-
treatment.  Therefore, bar height correlates how close the after-treatment 
contractility scores are to the pre-treatment contractility scores.  As denoted, 
some cells were assayed multiple times.  The right column shows siRNA 
knockdown efficiency. 
B.  Assay set-up.  Measurement of wrinkle lengths for quantification.  Please 
refer to Methods for details.  
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In order to assess whether β2-AR is required for contractility, siRNA was used to 
silence β2-AR in Hem-Pericytes, followed by contractility assay (Figure 20A, middle 
column).  β2-AR was chosen instead of β1-AR because of its relatively high expression 
in hemangioma tissues and hemangioma-derived cells compared to β1-AR.  After β2-AR 
siRNA treatment, relaxation of wrinkles in response to epinephrine (dark gray bar) and 
inhibition of this relaxation in response to propranolol (light gray bar) were no longer 
observed, most prominently for Hem-Pericytes 146 and 154.  No such effects of β2-AR 
siRNA were observed in Hem-Pericytes 156 and Hem-Pericytes from involuting phase 
because these cells were not responsive to the epinephrine and propranolol treatments 
prior to β2-AR knockdown (Figure 20A, middle column).  β2-AR knockdown efficiencies 
are shown, too (Figure 20A, right column).   
 
Contractility assays:  significance & caveats 
Not only are β1, 2-ARs, targets of propranolol, abundant in IH, but they may serve 
specific functions in Hem-Pericytes.  Indeed, contractility assays of Hem-Pericytes 146 
and 154 showed that cells relaxed in response to epinephrine, and this relaxation was 
inhibited by propranolol.  Silencing β2-AR with siRNA blunted these phenomena.  Hem-
Pericytes have not been studied extensively in literature, and contractility assays 
delineated their potential role in reduction of IH by propranolol.  Although contractility 
assays do not show whether whole hemangioma vessels contract in response to 
propranolol, they point to an effect of propranolol in Hem-Pericytes.  This may be 
important in finding mechanism(s) of propranolol in IH because pericytes surround small 
vessels and regulate their diameters by relaxing and contracting (Peppiatt, Howarth et 
al.  2006; Yemisci, Gursoy-Ozdemir et al.  2009).  
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On the other hand, for Hem-Pericytes 156, I-69, I-79 and I-82, cells showed 
relatively little relaxation in response to epinephrine compared to Hem-Pericytes 146 
and 154.  In addition, the inhibition of relaxation by propranolol was relatively small 
compared to Hem-Pericytes 146 and 154.  These responses were similar to those 
exhibited by human placental and retinal pericytes.  After silencing β2-ARs in Hem-
Pericytes 156, I-69, I-79 and I-82 with siRNA, the cellular contractility of all 4 conditions 
changed relatively little compared to their contractility before treatment.  This was also 
true for Hem-Pericytes 146 and 154.  In summary, as shown by the different responses 
of Hem-Pericytes in contractility assays, multiple factors may contribute towards 
contractility, in which β2-AR in Hem-Pericytes can be important.  This variability in 
contractility may be related to variability in clinical responses among IH patients treated 
with propranolol- 3% of IH patients did not respond to propranolol in a study 
(Bagazgoitia, Torrelo et al.  2011).  As noted in the figure, contractility assays were 
performed multiple times- 3 times for Hem-Pericytes 146 and twice for Hem-Pericytes 
156, I-69, human placental and retinal pericytes.  Combination of β2-AR siRNA 
knockdown and contractility assay was done twice each for Hem-Pericytes 146 and 
154.  Such reproducibility ensured that results from Figure 20 were legitimate. 
One caveat is that off-target effects of non-targeting siRNA were not assessed.  
Non-targeting siRNA did not affect proliferation of Hem-Pericytes 154, but it could have 
affected β2-AR levels of Hem-Pericytes in contractility assays.  Therefore, Hem-
Pericytes should have been transfected with no siRNA, non-targeting siRNA and β2-AR 
siRNA, and their β2-AR levels compared.  
66 
 
Another caveat is that Hem-Pericytes were in a state of contraction prior to the 
addition of reagents.  They were tested to detect loss of contraction or prevention of 
such loss of contraction in response to reagents.  If Hem-Pericytes were in a state of 
relaxation prior to the addition of reagents, they could have been tested to detect 
appearance of contraction.  Doing so may imitate contraction of Hem-Pericytes around 
hemangioma vessels, more so than the current set-up. 
Epinephrine, an agonist of β-ARs, needed to be added to cells in order to 
appreciate changes in their contractility; propranolol by itself did not change contractility 
of Hem-Pericytes much.  As noted above, this point raises the question of whether 
addition of an agonist, such as epinephrine, to cells in tube formation and proliferation 
assays would lead to different results.  Propranolol is an antagonist at β-ARs, so its 
effects may not be detected in the absence of an agonist.  An exception would be, 
however, if propranolol were an inverse agonist at β-ARs in IH.  Among tube formation, 
proliferation and contractility assays, propranolol was used in conjunction with 
epinephrine only in contractility assays.  Even though effects from combination of 
epinephrine and propranolol make β-ARs the likely targets of the drugs in contractility 
assays, phosphorylation status of the receptors and intracellular cAMP levels were not 
assessed, so this notion was not confirmed.  In summary, proliferation and contractility 
assays showed potential effects of propranolol on hemangioma-derived cells; 
proliferation assays hinted that propranolol is an inverse agonist, while contractility 
assays hinted that propranolol is an antagonist of β-ARs in IH. 
Finally, as described above, Hem-Pericytes were used in contractility assays 
because they contracted PDMS more readily than HemECs or HemSCs.  PDMS was  
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thermally cross-linked by passing over low flame twice.  If one were to decrease cross-
linking of PDMS by passing over low flame once, HemECs or HemSCs might be able to 
contract PDMS more readily.  However, this parameter was kept consistent for all cell 
types because changing it from one cell type to next might have given unfair advantage 
to certain cell types, thereby skewing results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
68 
 
 
 
 
 
 
 
 
 
 
 
Chapter V 
Reproduction of clinical effect in vivo 
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5.1 In vivo studies 
So far, the presence of β-ARs in IH has been confirmed, and Hem-Pericytes were 
identified as targets of propranolol in vitro; a functional assay was utilized to find that 
contractility of Hem-Pericytes was affected by propranolol.  In addition, propranolol 
reduced proliferation of HemECs and Hem-Pericytes over 5 days, which may be 
relevant in long-term efficacy in IH.  With these results in hand, the effects of 
propranolol were assessed in an in vivo model of IH. 
 
In vivo model of IH 
An in vivo model of disease gives researchers an appropriate environment to perform 
experiments, so a murine model of IH was developed.  All in vivo studies described here 
are covered under an animal protocol (10-11-1840R) approved by the Animal Care and 
Use Committee at Boston Children’s Hospital.  The Bischoff Laboratory showed that 
HemSCs, when suspended in Matrigel and subcutaneously implanted into nude/nude 
mice, formed hemangioma-like vessels within 7 days.  In the Matrigel sections, 
researchers detected GLUT-1
+ blood vessels, a diagnostic marker of IH.  It was also 
noted that the number of vessels decreased by 28 days, whereas adipocytes became 
more noticeable during the same time period.  These characteristics reproduced natural 
course of IH, providing researchers with an in vivo model (Khan, Boscolo et al.  2008). 
GFP-labeled HemSCs were shown to differentiate into both endothelial cells 
lining the lumen of the vessels and pericytes surrounding the vessels and at later time 
points, adipocytes (Khan, Boscolo et al.  2008; Boscolo, Mulliken et al.  2011).  
HemECs do not form vessels in this model when implanted alone, without a partner cell  
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that can differentiate into pericyte or smooth muscle cell.  Likewise, Hem-Pericytes do 
not form vessels in this model when implanted alone (Boscolo, Mulliken et al.  2013).  
However, HemECs co-implanted with Hem-Pericytes form vessels readily within 7 days.  
In summary, hemangioma-derived cells mixed with Matrigel form hemangioma-like 
vessels and adipocytes, thereby recapitulating key aspects of IH pathogenesis.  
Unfortunately, aspects such as tumor enlargement of proliferating phase and shrinkage 
of involuted phase are not observed in this model.   
 
5.2 Selecting HemSCs for in vivo experiments 
As described above, HemSCs express VEGF-A, which binds VEGFR-1 to differentiate 
HemSCs to HemECs in an autocrine manner (Boscolo, Mulliken et al.  2011).  The 
newly-differentiated HemECs then promote neighboring HemSCs to become Hem-
Pericytes by their expression of Jagged1, which was found critical for differentiation of 
HemSCs to Hem-Pericytes (Boscolo, Stewart et al.  2011).  Therefore, HemSCs were 
utilized to study effects of propranolol on hemangioma vessels. 
  The Bischoff Laboratory members have isolated numerous HemSCs over the 
years, and it was important to choose appropriate candidates among them for in vivo 
experiments.  With the help of Jill Wylie-Sears, a Bischoff Laboratory member, 11 
HemSCs, previously isolated by the laboratory, were tested.  She evaluated the 11 
HemSCs via flow cytometry and assessed for absence of CD31, commonly found on 
endothelial cells, and CD45, a hematopoietic cell marker, but presence of CD29, 
integrin β1 that is commonly expressed in many mammalian cells, and CD90, a 
mesenchymal marker (not shown).  While she evaluated the HemSCs by flow  
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cytometry, HemSCs were assessed for their proliferative potential using the indicated 
set-up (Figure 21). 
 
Thus, using immunostaining with DAPI as a read-out, proliferation rates of HemSCs 
were determined (Figure 22). 
 
 
 
 
Figure 21.  Proliferation assay set-up for HemSCs. 
HemSCs were assessed for their proliferation using the above set-up.  4', 6-
diamidino-2-phenylindole (DAPI) was used as an indicator of proliferation.  
Please refer to Methods for details. 
Figure 22.  Quantification of proliferation in HemSCs. 
A.  Six pictures of DAPI-stained nuclei were taken on Days 1, 4 and 7.  
Shown are representative pictures from HemSCs 140 and 147 on each day. 
B.  Proliferation graphs of HemSCs 140 and 147. 
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Combining results from flow cytometry and proliferation, the 11 HemSCs were divided 
into 2 groups- one group with the right flow cytometry profile and fast proliferation, and 
another group that did not fit either/both traits (Table 6). 
 
Table 6.  HemSCs categorized for in vivo studies. 
Candidates  Not candidates 
120 
127 
128 
129 
140 
149 
I-54 
122 
135 
147 
148 
 
In order to assess the candidates even further, their RNA levels of VEGF-A were 
determined.  As described above, VEGF was postulated to be a central molecule in the 
pathogenesis of IH.  VEGF-A can bind VEGFR-1 on HemSCs, which is important for 
their differentiation to HemECs.  HemSCs also express the highest levels of VEGF-A 
among the 3 hemangioma-derived cell types.  Therefore, candidates with high levels of 
VEGF-A were desirable, in addition to having the right flow cytometry profile and fast 
proliferation rates.  Cryovials of the 7 candidates from Table 6 were thawed, cells 
cultured, and their RNA levels of VEGF-A determined.  Samples other than the 7 
candidates were included for comparison (Figure 23).  Although cDNA samples of cells 
were loaded into triplicate wells for qRT-PCR, these provided technical replicates; cells 
were grown and harvested from single plates, from which RNA extracted and cDNA 
reverse-transcribed.  As they were not grown in multiple wells or plates, no error bars 
could be added to the graph.  
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According to Figure 23, HemSCs 128 and 129 seemed the most promising among the 7 
candidates for in vivo studies.  A comprehensive evaluation would have involved 
assessing levels of secreted VEGF-A by ELISA, as well as confirming endothelial and 
pericytic differentiation capabilities of the HemSCs in vitro.  Although HemSCs 125 and 
133 expressed higher levels of VEGF-A than the candidates in Figure 23, they were of 
limited availability. 
  In conclusion, HemSCs 128 and 129 were determined as candidates for in vivo 
studies based on flow cytometry characterization, proliferation rates and VEGF-A levels 
by qRT-PCR. 
 
 
 
 
Figure 23.  VEGF-A levels of the 
“candidate” HemSCs for in vivo studies. 
Ratios of VEGF-A to GAPDH are shown for 
the HemSCs & HDMECs.  HemSCs 127 and 
149 did not grow upon being thawed.  
HemSCs 125 & 133 and HDMECs are 
included for comparison.  
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5.3 Rationale for using micro-ultrasonography for in vivo analyses 
At the conclusion of in vivo experiments, researchers harvest the cell/Matrigels and 
prepare histological sections, from which additional analyses such as microvessel 
density (MVD) calculation and IHC can be performed.  Recently, researchers have used 
micro-ultrasonography to quantify vascular volume in areas of interest in mice and 
obtained valuable information.  Contrast agent is injected into animal circulation via 
cannulated tail vein and is confined within the vasculature, providing an indicator of 
vascular volume.  This information from areas of interest is collected by micro-
ultrasonography probe and quantified by Vevo2100 unit (VisualSonics; Kang, Allen et 
al.  2011). 
A major advantage of this method is the ability to collect data at multiple time 
points in the same animal, which adds depth to traditional methods like MVD calculation 
and IHC, in which data are collected at only one time point.  As noted above, patients 
treated with propranolol experience decrease in lesion firmness and redness within 24 
hours, so vascular volume reduction might be a reason for the efficacy of propranolol in 
IH.  Therefore, contrast-enhanced micro-ultrasonography provides a method to detect 
potential changes in vascular volume as a result of propranolol treatment. 
After persistent practice, I became proficient at cannulating murine tail veins to 
be able to inject contrast agent into animal circulation.  In addition, I received a formal 
training by VisualSonics staff and a personal training by Patrick Allen, a former Bischoff 
Laboratory member, to gain competency in using the Vevo2100 unit.  Thus, 
preparations were under way for utilizing micro-ultrasonography in in vivo experiments. 
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No reduction of vascular volume in vessels formed by HemSCs 
Initially, HemSCs were suspended in Matrigel and implanted into athymic nude/nude 
mice.  After vascular volume measurement on Day 7, mice were treated with either 
vehicle or propranolol for 7 days.  As noted above, HemSCs can differentiate to 
HemECs, which then promote neighboring HemSCs to differentiate to Hem-Pericytes. 
However, propranolol treatment did not significantly reduce vascular volume by 
Day 14, and difficulty was noted in achieving similar mean contrast values at the start of 
treatment on Day 7 (Figure 24B).  Explanted cell/Matrigels were analyzed for 
histological evaluation.  Twenty pictures from mid-Matrigel hematoxylin & eosin (H & E) 
sections of all animals in vehicle and propranolol groups were taken randomly with a 
microscope.  Luminal structures containing at least one red blood cell (RBC) were 
counted as a microvessel.  MVD was determined for the two groups and found to be 
statistically equivalent (Figure 24C).  In vivo experiments with HemSCs were performed 
a total of 6 times, with HemSCs 120, 128, 129 and 133, and Figure 24 shows data 
combined from 2 such experiments.  Additional data from micro-ultrasonography 
analyses are shown in the supplementary figure. 
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5.4 Propranolol reduced vascular volume in vessels formed by HemECs 158 and 
Hem-Pericytes 154 
In vivo studies with HemSCs were performed 6 times, but the clinical observation of 
vascular volume reduction after propranolol treatment was not reproduced.  Therefore, 
experimental set-up was re-evaluated, and it occurred that HemSCs needed to 
differentiate to HemECs and Hem-Pericytes and form hemangioma vessels in vivo in 7 
 
 
 Figure 24.  In vivo studies with HemSCs. 
Mice were implanted with HemSCs and Matrigel on Day 0.  Each group had 14 
mice.  After vascular volume measurement on Day 7, mice were treated with 
vehicle or propranolol for 7 days on Days 7-13. 
A.  Contrast values of individual mice on Days 7 and 14 are shown.   
B.  Line graphs represent changes in mean contrast values for each group.   
C.  MVD calculation.  N = 14 for each group. 
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days.  Hem-Pericytes that differentiated from HemSCs in vivo might not have expressed 
β2-AR as highly as fully differentiated Hem-Pericytes in vitro.  Therefore, they might 
have been less contractile. 
Therefore, HemECs and Hem-Pericytes, cell types more differentiated than 
HemSCs, were mixed in Matrigel and implanted into mice.  Similar mean contrast 
values at the start of treatment on Day 7 were achieved (Figure 25B), and mean 
contrast values of both groups (n = 17 for each) decreased by Day 14, but the drop from 
the propranolol group was significant, whereas that of the vehicle group was not (Figure 
25B).  This is the combined result of two separate experiments performed at different 
times; significant reduction of contrast values in the propranolol-treated group was 
noted each time.  On the other hand, MVD calculations from harvested Matrigels did not 
show significant differences between the two groups (Figure 25C).  
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Micro-ultrasonography analyses of vascular volume:  significance & caveats 
As described above, IH patients treated with propranolol experience decrease in 
redness and firmness of lesion relatively quickly, as early as 24 hours after initial 
treatment (Léauté-Labrèze, Dumas de la Roque et al.  2008; Sans, de la Roque et al.  
2009).  This quick turnaround led many to attribute vascular volume reduction of the 
tumor as a main reason for improvement.  Indeed, one group found that when lesions of 
 
  
 
 
Figure 25.  In vivo studies with HemECs 158 and Hem-Pericytes 154. 
Mice were implanted with HemECs 158, Hem-Pericytes 154 and Matrigel on 
Day 0.  Each group had 17 mice.  After vascular volume measurement on Day 
7, mice were treated with vehicle or propranolol for 7 days on Days 7-13. 
A.  Contrast values of individual mice on Days 7 and 14 are shown.   
B.  Line graphs represent changes in mean contrast values for each group. 
C.  MVD calculation.  N = 17 for each group. 
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IH patients, treated with propranolol, were measured with Doppler ultrasound, 
significant reductions in lesion volume and vessel density were detected.  In this study, 
patients received at least 4 weeks of propranolol treatment (Bingham, Saltzman et al.  
2012).  Vascular volume was reduced after 7 days of propranolol treatment in the in vivo 
experiments with HemECs 158 and Hem-Pericytes 154 in Figure 25.  To date, vascular 
volume reduction in an in vivo model of IH has not been reported after propranolol 
treatment.  MVD could only be calculated at one time point, on Day 14 in Figure 25, so 
even though MVD was equivalent for the 2 treatment groups, whether or not propranolol 
reduces vessel density over 7 days could not be determined. 
Propranolol is a non-selective β-AR antagonist and often prescribed to reduce 
blood pressure.  Even though vascular volume reduction was significant for the 
propranolol-treated group in the in vivo experiments with HemECs 158 and Hem-
Pericytes 154, this phenomenon might be attributed to the expected effect of the drug.  
However, some factors make this argument less persuasive.  First, vascular volume 
reduction was not significant for the in vivo experiments in which a different cell type, 
HemSCs only instead of HemECs and Hem-Pericytes, was used.  Second, micro-
ultrasonography analyses were performed one day after the last propranolol treatment, 
well past the half-life (3-5 hours) of the drug, so the noted vascular volume reduction 
was independent from the transient reduction of blood pressure by propranolol. 
One solution to this dilemma could have been measuring vascular volume of a 
structure (e.g., kidney) near cell/Matrigels- vascular volume reduction should be noted 
for cell/Matrigels, but not for the nearby structure, after propranolol treatment.   
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Unfortunately, this would have meant that mice would be under sedation much longer, 
approximately 1 hour/mouse under the current set-up (see Methods). 
As noted above, tumor enlargement of proliferating phase and shrinkage of 
involuted phase are not observed in the in vivo model.  Therefore, tumor size changes 
in response to propranolol can not be appreciated in the model.  In addition, IH patients 
are usually treated with 1-5 mg/kg of propranolol per day, whereas animals were treated 
twice daily with 5 mg/kg in Figures 24 and 25. 
In summary, despite some differences in details regarding treatment of IH 
patients and in vivo experiments using a murine model of IH, vascular volume reduction 
after propranolol treatment was noted in both.  This similarity gives further support to the 
notion that a reason behind efficacy of propranolol in IH patients is vascular volume 
reduction brought on by the contractile Hem-Pericytes. 
 
5.5 Histological evaluation of explanted cell/Matrigels 
Additional analyses were performed on the explanted cell/Matrigels.  The explanted 
cell/Matrigels were immunostained with human-specific CD31 antibody.  This was done 
because murine cells might have contributed to vessel formation in the in vivo studies.  
It was of interest to see whether the vascular volume reduction noted after propranolol 
treatment could be attributed to effects on the injected HemECs 158 and Hem-Pericytes 
154, instead of murine cells.  Brownish, luminal structures containing at least one RBC 
were counted as a human CD31
+ vessel.  Significant differences in the number of 
human CD31
+ vessels were noted, in which the propranolol-treated group exhibited 
higher numbers of human vessels (Figure 26A).  
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Vessel areas were measured in the explanted cell/Matrigels and compared 
between the 2 treatment groups.  This was performed because the differences in 
vascular volume after propranolol treatment might have resulted from differences in 
vessel areas; larger vascular volume from larger vessels and smaller vascular volume 
from smaller vessels.  If Hem-Pericytes contracted around hemangioma vessels in 
Matrigels after propranolol treatment, the vessel areas might have been smaller 
compared to those of Matrigels from the vehicle-treated mice.  However, no significant 
differences in vessel areas were noted between the two treatment groups (Figure 26B). 
As noted above, propranolol decreased proliferation of Hem-Pericytes 154 in 
vitro.  In order to assess whether the same phenomenon occurred in vivo, the explanted 
cell/Matrigels were immunostained with a marker of proliferation, Ki67, and a marker of 
pericytes, αSMA.  However, no significant differences in the number of Ki67
+/αSMA
+ 
cells were noted between the two treatment groups (Figures 26C, D).  
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Histological evaluation of explanted cell/Matrigels:  significance & caveats 
As described above, micro-ultrasonography analyses of the in vivo experiments with 
HemECs 158 and Hem-Pericytes 154 showed that vascular volume decreased in the 
group treated with propranolol.  Vascular volume was quantified by scanning the entire 
 
 
 
 
Figure 26.  Additional histological data from in vivo experiments with 
HemECs 158 and Hem-Pericytes 154. 
A.  Human CD31
+ vessels in Matrigels.  N = 17 for each group.  B.  Vessel 
areas in Matrigels.  N = 17 for each group.  C.  Ki67
+/αSMA
+ cells in Matrigels.  
N = 17 for each group.  D.  Example pictures. 
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length of the Matrigels.  The vessel numbers of explanted cell/Matrigels in both groups 
were statistically equivalent (Figure 25C).  As noted above, vessels are human and 
murine luminal structures with at least one RBC on H & E sections of explanted 
cell/Matrigels.  Therefore, extending the results from contractility assays, in which Hem-
Pericytes remained contracted in response to propranolol, these results point to an 
effect of propranolol, in which pericytes contract vessels to reduce vascular volume.  On 
the other hand, no differences in vessel numbers were detected after propranolol 
treatment, in contrast to reduced proliferation of HemECs and Hem-Pericytes in vitro.  
An important difference in experimental set-up is that vascular volume was quantified 
from the entire length of the Matrigels, approximating 3-dimensions, whereas 
histological evaluation of explanted cell/Matrigels was assessed from specific Matrigel 
sections, not as closely approximating 3-dimensions as vascular volume measurement.  
This difference might have influenced all results from histological evaluation of 
explanted cell/Matrigels. 
More vessels formed with HemECs and Hem-Pericytes (Figure 25C) compared 
to HemSCs alone (Figure 24C).  In terms of time, after implantation, HemECs and Hem-
Pericytes had to find relative positions in Matrigel to form hemangioma vessels within 7 
days, whereas HemSCs had to first differentiate to HemECs and Hem-Pericytes, which 
then had to find their relative positions to form vessels within the same duration, 7 days.  
This may explain the higher MVDs with HemECs and Hem-Pericytes compared with 
HemSCs alone. 
On the other hand, MVD calculations might have yielded different numbers had 
different criteria been used.  As listed in Methods, luminal structures containing at least  
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one RBC were counted as a microvessel, but absence of lumen or RBC may not 
necessarily rule out existence of vessel.  Researchers have used various markers such 
as CD31, a marker of endothelial cells, and CD34, a marker of endothelial and 
hematopoietic cells, to calculate MVD (de la Taille, Katz et al.  2000).  Others have used 
von Willebrand factor, a protein produced by endothelium and endothelial stroma that 
helps prevent excessive bleeding, to calculate MVD (Weidner, Carroll et al.  1993).  For 
both examples, presence of neither lumen nor RBC was required to constitute a 
microvessel, and areas with the greatest density of positive endothelial cells were 
selected for counting.  Therefore, MVD calculations might have given higher numbers 
had different criteria been used. 
As noted above, numbers of human CD31
+ vessels were determined because it 
was of interest to find out whether vascular volume reduction from propranolol treatment 
could be attributed to drug effect on human, not murine, vessels.  Given the statistically 
equivalent numbers of total vessels in both groups, the numbers of human CD31
+ 
vessels were expected to be statistically equivalent again.  However, the number of 
human CD31
+ vessels was significantly higher in the propranolol-treated than in the 
vehicle-treated mice, which was unexpected (Figure 26A).  In addition, the numbers of 
human CD31
+ vessels (Figure 26A) and total vessels in the propranolol-treated group 
(Figure 25C) were similar, which was surprising.  A possible reason for this finding is 
experimental set-up, which should have been modified.  Researchers from the Bischoff 
Laboratory used plant lectins specific for human or murine endothelium to demonstrate 
that 3 types of vessels are detected when human cells are implanted on mice:  human 
vessels, murine vessels and chimeric vessels containing both human and murine  
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endothelium (Kang, Allen et al.  2011).  All brownish, luminal structures containing at 
least one RBC were counted as a human CD31
+ vessel, and these included structures 
that appeared brown only in parts of the lumen.  Therefore, a more extensive evaluation 
would have used such lectins specific for human or murine endothelium to categorize 
vessels into human, murine or chimeric vessels. 
Although vessel areas of explanted cell/Matrigels in the in vivo experiments with 
HemECs 158 and Hem-Pericytes 154 were statistically equivalent or numerically larger 
for mice treated with propranolol than those treated with vehicle, the vessel areas of 
both groups prior to treatment were unknown; this is a limitation of histological 
evaluation.  Therefore, whether vascular volume was reduced because of contraction of 
Hem-Pericytes in vivo could not be confirmed. 
Propranolol reduced proliferation of Hem-Pericytes 154 in vitro.  Whether this 
anti-proliferative effect contributed to the decrease in vascular volume was addressed 
by analyzing the proliferative status of αSMA
+ cells in the explanted cell/Matrigels from 
the in vivo experiments with HemECs 158 and Hem-Pericytes 154 (Figure 26C).  
Matrigel sections were immunostained with Ki67 and αSMA, and double-positive cells 
were counted.  There was no significant difference between the two treatment groups.  
Thus, the anti-proliferative effect of propranolol on Hem-Pericytes was not evident 14 
days after cell/Matrigel implantation.  This might have been because of several 
differences in experimental designs between in vitro proliferation assays and in vivo 
assays using murine model of IH.  For instance, PBS or propranolol was directly added 
to wells containing Hem-Pericytes in in vitro assays on Days 1-5 (Figure 17B).  On the 
other hand, HemECs and Hem-Pericytes were mixed with Matrigel and subcutaneously  
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implanted on nude mice.  After allowing 7 days to pass for hemangioma vessel 
formation in Matrigel, animals were treated with vehicle or propranolol, first metabolized 
by murine liver before distribution to rest of body, on Days 7-13.  These may be 
contributing factors behind lack of difference between the groups in Figure 26C. 
The anti-proliferative effect of propranolol on HemECs was not assessed in vivo 
by immunostaining with Ki67 and CD31, which should be performed in the future. 
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6.1 Isolation of hemangioma-derived cells and in vitro culture 
Specimens of IH were obtained under a human subject protocol approved by the 
Committee on Clinical Investigation, Boston Children’s Hospital (04-12-175R).  The 
clinical diagnosis was confirmed by the Department of Pathology, and informed consent 
was obtained from parents of patients.  HemECs, Hem-Pericytes and HemSCs were 
isolated as described below. 
For all hemangioma-derived cells, freshly-resected hemangioma tissues were 
placed on ice, washed in PBS and minced into ~ 1 mm pieces.  Tissues were digested 
in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 2% FBS (HyClone 
SV30014.03), 1x Ca
2+, 1x Mg
2+, 1x PSF (100 U/ml penicillin, 100 µg/ml streptomycin, 
0.25 µg/ml amphotericin; Invitrogen 15240-096) and 0.2% collagenase A (Roche 
11088785103) for 30 minutes at 37 ˚C.  Afterwards, tissues were homogenized with a 
pestle in a 50 mL conical tube, and the supernatant filtered with a 100 µm cell strainer 
(BD Falcon 352360).  The filtered supernatant was centrifuged at 1500 rpm for 10 
minutes, and the resulting pellet re-suspended in PBS/0.6% ACD-A/0.5% BSA, which is 
composed of 22.3 g of glucose, 22 g of sodium citrate, 8 g of citric acid in 1 L of dH2O.  
From here, steps diverged for HemECs, Hem-Pericytes and HemSCs isolations. 
For HemECs, endothelial cells were selected using anti-CD31-coated magnetic 
beads (Dynal 111.55).  The CD31+ cells were cultured on fibronectin-coated (1 µg/cm
2, 
Chemicon FC-010) plates with endothelial basal medium (EBM-2, Lonza CC-3156).  
EBM-2 was supplemented with 20% FBS, endothelial growth media-2 SingleQuots 
(EGM-2 SingleQuots, Lonza CC-4176) without hydrocortisone and 1x GPS (Cellgro 30- 
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009-CI).  HemECs were tested for endothelial markers like CD31, CD146 and VE-
cadherin (Boye, Yu et al.  2001). 
  For Hem-Pericytes, cells were seeded on non-coated tissue culture plates in 
DMEM 10% FBS, 1x GPS (Cellgro 30-009-CI), which provided a selective growth 
advantage.  The resulting cell populations were tested for markers of pericytes like 
αSMA, calponin, NG2, PDGFR-β and smMHC (Boscolo, Mulliken et al.  2013). 
  For HemSCs, cells were selected with anti-CD133-coated magnetic beads 
(Miltenyi Biotec 130-050-80).  As described above for HemECs, the CD133+ cells were 
cultured on fibronectin-coated (1 µg/cm
2) plates with EBM-2, supplemented with 20% 
FBS, EGM-2 SingleQuots without hydrocortisone and 1x GPS (Cellgro 30-009-CI).  
HemSCs were tested for positivity of markers like CD90 and Oct-4, negativity of CD31 
and hematopoietic cell marker CD45 and their ability to differentiate to HemECs and 
Hem-Pericytes (Khan, Boscolo et al.  2008). 
 
6.2 Non-hemangioma cell and tissue culture 
Human umbilical vein endothelial cells (HUVECs) were kindly provided by the Vascular 
Research Division at the Brigham & Women’s Hospital (Chavakis, Kanse et al.  1998).  
Human dermal microvascular endothelial cells (HDMECs) were isolated from neonatal 
foreskin obtained by human subject protocol, approved by the Partners Human 
Research Committee, Brigham & Women’s Hospital (1999-P-002486/14; Kräling and 
Bischoff 1998).  HUVECs and HDMECs were cultured on fibronectin-coated (1 µg/cm
2) 
plates with EBM-2, supplemented with 20% FBS, EGM-2 SingleQuots without 
hydrocortisone and 1x GPS (Cellgro 30-009-CI).  bmMPCs were cultured on fibronectin- 
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coated (1 µg/cm
2) plates with EBM-2, supplemented with 20% FBS, EGM-2 
SingleQuots (without heparin, hFGF-B, hydrocortisone and VEGF) and 1x GPS (Cellgro 
30-009-CI).  Human placental and retinal pericytes were purchased from Promocell (C-
12981) and Cell Systems (ACBRI 183), respectively and grown in DMEM 10% FBS, 1x 
GPS (Cellgro 30-009-CI).  Smooth muscle cells (SMCs) from bladder, bronchus and 
colon were purchased from ScienCell (HBdSMC, HBSM and HCoSMC, respectively), 
generously provided by Rosalyn Adam and cultured in smooth muscle cell media from 
ScienCell (Cat. 1101).  Human cardiac tissue was generously provided by Bernhard 
Kühn (protocol Z06-10-0489).  Bovine retinal pericytes were generously provided by 
Jennifer Durham.  They were cultured in DMEM supplemented with 10% bovine calf 
serum (Atlanta Biologicals S11450), 1x antibiotic-antimycotic (Gibco 15240) and 1x L-
glutamine (Gibco 25030). 
 
6.3 Tube formation assay 
Into each well of a 24-well plate (Costar 3526), 300 µL of thawed, growth factor-reduced 
Matrigel (BD Biosciences 354230) were dispensed.  The Matrigel was allowed to solidify 
in a 37 ˚C incubator for 20 minutes.  Sixty thousand cells in 500 µl of EBM-2, 
supplemented with 0.1% BSA , were seeded onto each well of solidified Matrigel at 3.0 
x 10
4 cells/cm
2.  The media, in which cells were suspended, contained vehicle or 10 µM 
of propranolol.  Vehicle, closely resembling an injectable solution of propranolol 
(Sandoz NDC 0781-3777-95, 1 mg/mL), was prepared by Boston Children’s Hospital 
Pharmacy.  After 18 hours, pictures of cells were taken under bright field at 10X (Nikon 
Eclipse TS100).  
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6.4 5-HT1B immunostaining (IF) 
Formalin-fixed, paraffin-embedded IH tissues and brain tissues (obtained from 
Department of Pathology, Boston Children’s Hospital) were deparaffinized in xylene and 
hydrated through sequential ethanol gradient.  Antigen was retrieved by heating the 
sections in 1x antigen unmasking solution (Vector H-3300) at 90-95 ˚C for 23 minutes.  
The sections were blocked with 5% goat serum (Vector S-1000) for 30 minutes and 
incubated with rabbit anti-5-HT1B receptor (1:100, abcam ab85937) or rabbit IgG (1:100, 
Vector I-1000) for 1 hour and followed by Alexa Fluor 488-conjugated anti-rabbit IgG 
(1:200, Invitrogen A11034) for 1 hour.  The sections were washed in PBS and mounted 
with medium containing DAPI (Vector H-1200).  Pictures were taken at 40X using Leica 
TCS SP2 Acousto-Optical Beam Splitter confocal system with DMIRE2 inverted 
microscope- diode 405 nm, argon 488 nm and HeNe 594 nm. 
 
6.5 α1b- and β2-ARs immunostaining (DAB) 
Formalin-fixed, paraffin-embedded IH tissues and brain tissues (obtained from 
Department of Pathology, Boston Children’s Hospital) were deparaffinized in xylene and 
hydrated through sequential ethanol gradient.  Antigen was retrieved by heating the 
sections in 1x antigen unmasking solution (Vector H-3300) at 90-95 ˚C for 23 minutes.  
The sections were blocked with 5% goat serum (Vector S-1000) for 30 minutes and 
incubated with rabbit anti-α1b-AR (1:200, abcam ab84405), rabbit anti-β2-AR (1:200, 
Novus NBP1-19449), rabbit anti-β2-AR (1:200, abcam ab61778) or rabbit IgG (1:200, 
Vector I-1000) for 1 hour.  Peroxidase was quenched by incubating in 3% H2O2 for 5 
minutes.  This was followed by incubation with peroxidase labeled anti-rabbit IgG  
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(1:200, Vector PI-1000) for 1 hour.  DAB enhancing solution (ImmPACT DAB Cat# SK-
4105) was applied, which was followed by Hematoxylin QS (Vector H-3404).  Sections 
were dehydrated through sequential ethanol gradient.  They were then washed in 
xylene and mounted with Permount (Fisher SP15-100).  Pictures were taken at 20X with 
a microscope (Zeiss Axiophot II, equipped with AxioCam MRc5  and supplemented with 
AxioVision Rel. 4.8 software). 
 
6.6 quantitative real time polymerase chain reaction (qRT-PCR) 
RNAs from cells and tissues were extracted using RNeasy Micro kit (Qiagen 74004) 
and TRIzol (Invitrogen 15596-026), respectively.  Concentrations and ratios of 260/230 
and 260/280 were measured with Nanodrop 8000 Spectrophotometer (Thermo).  
Samples with 260/230 and 260/280 ratios greater than 1.7 were chosen, and their 
cDNAs synthesized with Quanta qScript cDNA Synthesis kit (VWR Scientific 10414-
098).  Primers for qRT-PCR are listed in Table 1.  Reactions were prepared with SYBR 
Green master mix (Roche 04913850001) and performed on Applied Biosystems’ 
StepOnePlus Real-Time PCR system for primers of ARs and β-actin according to the 
following:  initial denaturation at 95 °C for 10 minutes, followed by 40 cycles of 
denaturation at 95 °C for 15 seconds and annealing at 53 °C for 1 minute.  Afterwards, 
temperature was raised to 95 °C before it was lowered for melting curve detection from 
48 to 95 °C, by 0.3 °C increment. 
These steps were modified for primers of 5-HT1B receptor, GAPDH, HPRT1, S9 
and VEGF-A because of higher melting temperatures, according to the following:  initial 
denaturation at 95 °C for 10 minutes, followed by 40 cycles of denaturation at 95 °C for  
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15 seconds and annealing at 60 °C for 1 minute.  Afterwards, temperature was raised to 
95 °C before it was lowered for melting curve detection from 55 to 95 °C, by 0.3 °C 
increment. 
 
Table 7.  Sequences of primers for qRT-PCR. 
Gene  Forward  Reverse 
5-HT1B 
receptor 
5’-
CTGTGTATGTGAACCAAGTC-
3’ 
5’-
TAGGGAGATGATGAAGAAGGG-
3’ 
α1b-AR  5’-
GATCCATTCCAAGAACTTTCA
C-3’ 
5’-CAGAACACCACCTTGAACAC-
3’ 
β1-AR  5’-
TCTTTTGTGTGTGCGTGTGA-
3’ 
5’-ATGCTTCTCCCTTCCCCTAA-
3’ 
β2-AR  5’-
CACCAACTACTTCATCACTTC
AC-3’ 
5’-GACACAATCCACACCATCAG-
3’ 
β3-AR  5’-
TGAAATCCAGTTGCCATTGA-
3’ 
5’-CACCATGTAAGGCACCACTG-
3’ 
β-actin  5’-
TGAAGTGTGACGTGGACATC-
3’ 
5’-GGAGGAGCAATGATCTTGAT-
3’ 
GAPDH  5’-TGCACCACCAACTGCTTAG-
3’ 
5’-GATGCAGGGATGATGTTC-3’ 
HPRT1  5’- 
TGGACAGGACTGAACGTCTT
G-3’ 
5’- 
CCAGCAGGTCAGCAAAGAATTT
A-3’ 
S9  5’-
GATTACATCCTGGGCCTGAA-
3’ 
5’-ATGAAGGACGGGATGTTCAC-
3’ 
VEGF-A  5’-
AGCCTTGCCGCCTTGCTGCT
CTA-3’ 
5’- GTGCTGGCCTTGGTGAGG-3’ 
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6.7 Cellular proliferation in response to propranolol 
Three thousand, seven hundred fifty HemECs, HemSCs and HDMECs in 150 µL of 
EBM-2, supplemented with 20% FBS, EGM-2 SingleQuots without hydrocortisone and 
1x GPS (Cellgro 30-009-CI) were plated into each well of a 48-well plate (BD Falcon 
353078), at a density of 5000 cells/cm
2.  Likewise, 3750 pericytes in 150 µL of DMEM 
10% FBS, 1x GPS (Cellgro 30-009-CI) were plated into each well of a 48-well plate, at a 
density of 5000 cells/cm
2.  For each cell type, two additional wells were plated at a 
density of 5000 cells/cm
2 to determine the number of attached cells, 24 hours after 
plating (Day 1).  Cells were treated twice daily with PBS or 10 µM of propranolol 
(Sandoz NDC 0781-3777-95, 1 mg/mL at pH 4) from Day 1 to 5.  Cells were counted in 
quadruplicate wells using an automated cell counter (Millipore Scepter 2.0, Cat # 
PHCC20060).  All particles whose diameters ranged 10-25 µM were counted. 
 
6.8 siRNA transfection 
Non-targeting #3, β1- and β2-AR siRNAs were designed by and purchased from 
Dharmacon (D-001810-03-05, L-005425-00-0005 and L-005426-01-0005, respectively).  
Non-targeting siRNA #3 has no homology to any known human gene, and its off-target 
effects have been minimized.  β1- and β2-AR siRNAs were each a pool of 5 siRNAs, 
designed to maximize knockdown.  Hem-Pericytes 154 grew in DMEM 10% without 
antibiotics until they reached 60-90% confluence on 12-well plates (Costar 3512).  Cells 
were then transfected with 10 nM of siRNA of interest using Lipofectamine RNAiMAX 
(Life Technologies, 13778-075), prepared in reduced-serum media (Gibco OPTI-MEM I 
31985).  The cells were trypsinized 24 hours after transfection and prepared for  
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contractility, proliferation assays or re-plated on 12-well plates to assess extent of 
knockdown by qRT-PCR.  Contractility assay and assessment of knockdown by qRT-
PCR were performed 48 hours after transfection.  Proliferation assay was performed for 
5 days following transfection. 
 
6.9 Contractility assay 
Six-and-a-half microliters of polydimethylsiloxane (PDMS) from Sigma-Aldrich 
(DMPS12M-100G, viscosity 12,500 cST) were pipetted onto marked, round glass 
coverslips (Fisher Scientific 12-545-81) with a positive displacement pipette (Gilson 
F148502) and spread for one hour at 40 °C.  PDMS were thermally cross-linked by 
passing over low flame twice, and then coated with electrical charge for 13 seconds 
using a plasma etcher (SPI Plasma-Prep II 11005).  They were then covered with 0.1 
mg/mL of type I collagen from rat (BD Biosciences 354236) suspended in PBS.  Each 
coverslip was placed into a well of a 24-well plate (Costar 3526).  The 24-well plate was 
UV-irradiated for five minutes, and 4000 cells in DMEM 2% FBS, 1x GPS (Cellgro 30-
009-CI) were pipetted into each well.  After 48 hours, pictures of wrinkled cells, in 
relation to marks on coverslips, were taken under bright field at 10X (Nikon Eclipse 
TS100). 
After pictures were taken, cells were treated with 10 µM of one of the following 
four conditions by a Bischoff Laboratory member:  vehicle (n = 6 wells), propranolol (n = 
6), vehicle & epinephrine (n = 6) or propranolol & epinephrine (n = 6).  As noted above, 
vehicle that closely resembled the solution in which intravenous propranolol is 
suspended (Sandoz NDC 0781-3777-95, 1 mg/mL at pH 4) was prepared by Boston  
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Children’s Hospital Pharmacy.  Epinephrine 1:1000 was also purchased from the same 
pharmacy (Hospira NDC 0409-7241-01, 1 mg/mL).  Within an hour after addition of 
reagents, pictures of the same cells were taken again.  I was blinded to the treatments 
until after the pictures were taken.  Contractility for each cell and all four conditions were 
quantified using the following formula:  C = N x L, N = # wrinkles and L = length in pixels 
from ImageJ (Markhotina, Liu et al.  2007). 
 
6.10 Proliferation assay of HemSCs 
HemSCs were cultured in EBM-2, supplemented with 20% FBS, EGM-2 SingleQuots 
without hydrocortisone and 1x GPS (Cellgro 30-009-CI).  Autoclaved, round glass 
coverslips (Fisher Scientific 12-545-81) were placed in 3 wells of 4-well plates (Nunc 
176740).  For each HemSCs, 3, 4-well plates were prepared for counting on Days 1, 4 
and 7.  Coverslips were then coated with 1% gelatin in ddH2O (pH adjusted to 7.5 and 
sterile-filtered).  Five thousand HemSCs were seeded onto each well (1.9 cm
2) at a 
density of 2632 cells/cm
2.  On Days 1, 4 and 7, cells were fixed with 4% 
paraformaldehyde for 5 minutes and washed with PBS.  A needle and forceps were 
used to flip coverslips with cells on them, onto a microscope glass slide (Fisher 12-550-
15) with drops of medium containing DAPI (Vector H-1200).  Fluorescent pictures of 
nuclei were taken at 10X (Nikon Eclipse TS100).  Two pictures were taken for each 
coverslip, for a total of six pictures each on Days 1, 4 and 7.  The numbers of nuclei 
were calculated using ImageJ, and the 6 counts averaged for cell numbers on Days 1, 4 
and 7. 
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6.11 In vivo model of infantile hemangioma 
Initially, 2.5 million HemSCs were suspended in 250 µl of Matrigel (BD Biosciences 
356237) and injected subcutaneously on the backs of 20, 6-week old male athymic 
nude/nude mice (Massachusetts General Hospital, Boston, MA).  This experimental set-
up was performed a total of 6 times, with HemSCs 120, 128, 129 and 133, but no 
significant changes in vascular volume were detected after propranolol treatment for 7 
days. 
Therefore, hemangioma vessels were formed using HemECs and Hem-
Pericytes, based on the rationale that the more differentiated cells might form vessels 
that resemble the vessels in a well-established IH.  A mixture of HemECs 158 and Hem-
Pericytes 154, 1.25 million cells from each cell type, was suspended in 250 µl of 
Matrigel and injected subcutaneously on the backs of 20, 6-week old male athymic 
nude/nude mice. 
For experiments involving HemSCs alone & HemECs 158 and Hem-Pericytes 
154, two mice were set aside from the rest of group and injected with 250 µl of Matrigel 
without any cells, to serve as negative controls.  Mice whose Matrigels had contrast 
values at day 7 above those of negative controls were continued further in experiment, 
whereas those that did not were sacrificed.  The surviving mice were then paired by 
their contrast values and divided into either the vehicle or propranolol treatment group; 
this was to ensure that each group had a similar distribution of contrast values at the 
start of treatment.  Then, either the vehicle or propranolol at 5 mg/kg, twice a day for 7 
days, was injected into their peritoneum.   
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6.12 Micro-ultrasonography analysis of vascular volume 
Seven days after implanting cells and Matrigel or Matrigel alone, the Matrigel implants 
were subjected to contrast-enhanced micro-ultrasonography using VisualSonics’ Vevo 
2100 unit. 
Mice were sedated using isoflurane, targeting respiratory rate of 50 per minute.  
Tail veins of mice were cannulated using modified, winged infusion set (Allegro Medical 
549230), through which nontargeted contrast agent (VisualSonics VS-11913) was 
injected to quantify vascular volume in Matrigels.  A micro-ultrasonography probe, 
mounted on a motor, scanned the length of the Matrigels in 0.1 mm segments, and the 
amount of contrast agent was quantified by the Vevo 2100 unit.  Twenty minutes 
passed for contrast agent to be cleared from murine circulation, and the above steps 
were repeated.  The two measurements were averaged to determine contrast values of 
mice.  The above steps took approximately an hour per mouse. 
After 7 days of treatment, contrast values of cell/Matrigel implants were 
determined as above. 
 
6.13 Microvessel density (MVD) 
Twenty pictures from mid-Matrigel H & E sections of all animals in vehicle and 
propranolol groups were taken randomly at 40X with a microscope (Zeiss Axiophot II, 
equipped with AxioCam MRc5  and supplemented with AxioVision Rel. 4.8 software).  
Luminal structures containing at least one RBC were counted as a microvessel.  The 
average MVD counted in 20 pictures was expressed as vessels/mm
2. 
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6.14 Human CD31
+ vessel calculation 
Formalin-fixed, paraffin-embedded mid-Matrigel sections, from in vivo experiments with 
HemECs 158 and Hem-Pericytes 154, were deparaffinized in xylene and hydrated 
through sequential ethanol gradient.  Antigen was retrieved by heating the sections in 
1x antigen unmasking solution (Vector H-3300) at 90-95 ˚C for 23 minutes.  The 
sections were blocked with 5% horse serum (Vector S-2000) for 30 minutes and 
incubated with mouse anti-human CD31 (1:40, Dako M0823) or mouse IgG (1:40, Dako 
X0931) for 1 hour.  Peroxidase was quenched by incubating in 3% H2O2 for 5 minutes.  
This was followed by incubation with peroxidase labeled anti-mouse IgG (1:200, Vector 
PI-2000) for 1 hour.  DAB enhancing solution (ImmPACT DAB Cat# SK-4105) was 
applied, which was followed by Hematoxylin QS (Vector H-3404).  Sections were 
dehydrated through sequential ethanol gradient.  They were then washed in xylene and 
mounted with Permount (Fisher SP15-100).  Twenty pictures were taken randomly at 
40X with a microscope (Zeiss Axiophot II, equipped with AxioCam MRc5  and 
supplemented with AxioVision Rel. 4.8 software).  Brownish, luminal structures 
containing at least one RBC were counted as a human CD31
+ vessel.  The average of 
the 20 pictures was expressed as human CD31
+ vessels/mm
2. 
 
6.15 Vessel area calculation 
The areas of microvessels used in MVD calculations, from in vivo experiments with 
HemECs 158 and Hem-Pericytes 154, were measured using ImageJ and expressed as 
pixel
2. 
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6.16 Ki67 & αSMA immunostaining 
Formalin-fixed, paraffin-embedded mid-Matrigel sections, from in vivo experiments with 
HemECs 158 and Hem-Pericytes 154, were deparaffinized in xylene and hydrated 
through sequential ethanol gradient.  Antigen was retrieved by heating the sections in 
1x antigen unmasking solution (Vector H-3300) at 90-95 ˚C for 23 minutes.  The 
sections were blocked with 5% goat serum (Vector S-1000) for 30 minutes and 
incubated with rabbit anti-Ki67 (1:100, abcam ab66155) or rabbit IgG (1:100, Vector I-
1000) for 1 hour and followed by FITC-conjugated anti-rabbit IgG (1:200, Vector FI-
1000) for 1 hour.  The sections were washed in PBS and then blocked again with 5% 
horse serum (Vector S-2000) for 30 minutes and incubated with mouse anti-αSMA 
(1:750, Sigma A2547) or mouse IgG (1:750, Vector I-2000) for 1 hour and followed by 
Texas Red-conjugated anti-mouse IgG (1:200, Vector TI-2000) for 1 hour.  The sections 
were washed in PBS and mounted with medium containing DAPI (Vector H-1200).  Ten 
pictures were taken at 63X using Leica TCS SP2 Acousto-Optical Beam Splitter 
confocal system with DMIRE2 inverted microscope- diode 405 nm, argon 488 nm and 
HeNe 594 nm.  Cells with both green and red colors were counted, averaged and 
expressed as Ki67
+ & αSMA
+ cells/mm
2.  
 
6.17 Statistical analysis 
Proliferation data of hemangioma-derived cells and IHC data from in vivo experiments 
(MVDs, human CD31
+ vessels, vessel areas and Ki67
+ and αSMA
+ cells) were analyzed 
by two-tailed, unpaired t-tests.  
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Contrast values of mice injected with HemSCs and HemECs 158 and Hem-
Pericytes 154 were analyzed by two-tailed, paired t-tests.  All data analyses were 
performed using GraphPad Prism Version 5.04, and differences were considered 
significant when p < 0.05.  Dr. David Zurakowski, a biostatistician at Boston Children’s 
Hospital, was consulted regarding statistical analyses of data from micro-
ultrasonography experiments. 
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Chapter VII 
Conclusions 
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Summary 
β1,2-ARs are known receptors of the drug and confirmed to be abundant in IH by qRT-
PCR.  Proliferation of HemECs and pericytes, including Hem-Pericytes, was reduced by 
propranolol.  An in vitro contractility assay detected that propranolol affected contractility 
of Hem-Pericytes.  The importance of β2-AR in contractility of Hem-Pericytes was 
verified by siRNA knockdown.  IH patients treated with propranolol experienced 
decrease in vascular volume that was reproduced in vivo in a murine model of IH.  
Thus, HemECs and Hem-Pericytes are potential cellular targets of propranolol in IH. 
 
Possibility of additional cell types affected by propranolol 
In vivo experiments using a murine model of IH showed that propranolol reduced 
vascular volume.  Although quantification of human CD31
+ vessels in explanted 
cell/Matrigels showed that the implanted HemECs formed vessels, vascular volume 
reduction might not have been solely accomplished through effect of propranolol on 
hemangioma-derived cells.  This notion is plausible because the implanted cells in 
Matrigel form vascular networks that are perfused as a result of connection to murine 
circulation.  Therefore, various types of murine cells have access to the vascular 
networks within Matrigels. 
One example of such cell type is mast cells.  A group of researchers quantified 
and compared numbers of mast cells in tissue sections from IH, other vascular 
anomalies such as port wine stain, arteriovenous malformation and normal skin.  They 
found high numbers of mast cells in proliferating and involuting phases of IH, with the 
number in proliferating phase higher than that in involuting phase.  The number of mast  
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cells decreased over the course of IH, so that in late involuting phase its number was 
similar to those found in other vascular anomalies and normal skin.  The researchers 
postulated that mast cells might play a role in the involution of IH (Pasyk, Cherry et al.  
1984).  Although mast cells were not quantified in the in vivo experiments described 
above, they are an example of a murine cell type that could have contributed to vascular 
volume reduction after propranolol treatment. 
Endothelial cells synthesize molecules, such as von Willebrand factor, P-selectin 
and angiopoietin-2, and store them in Weibel-Palade bodies.  Upon binding of IgE, mast 
cells release their contents, which include cytokines, heparin and histamine.  In 
response to histamine, contents of the Weibel-Palade bodies are released from 
endothelial cells, and angiopoietin-2 contributes to vessel destabilization and 
angiogenesis.  This sequence of events may be relevant in IH pathogenesis, and mast 
cells express β2-AR, whose agonism may decrease the release of histamine (Johnson 
2002).  Paradoxically, a β-AR antagonist such as propranolol had no effect on release 
of histamine by mast cells (Ind, Barnes et al.  1985); nevertheless, effects of propranolol 
on mast cells in IH present an intriguing area of study. 
Propranolol treatment reduced vascular volume in hemangioma vessels that 
formed as a combination of HemECs and Hem-Pericytes.  As described above, the 
Bischoff Laboratory isolated HemECs, Hem-Pericytes and HemSCs from IH.  Although 
these 3 cell types have allowed researchers to study many questions and provided 
valuable knowledge, efficacy of propranolol in IH may also occur through a cell type yet 
to be isolated from IH. 
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Possibility of propranolol affecting natural course of IH 
Clinicians noted that oral propranolol, 2 mg/kg per day, is an effective, safe treatment 
for IH in 97% of patients.  However, 17% of patients experienced rebound in size and 
color after cessation of treatment (Zaher, Rasheed et al.  2011).  The occasional 
rebound in IH after cessation of propranolol treatment was also reported by different 
clinicians at various locations (Awadein and Fakhry  2011; Missoi, Lueder et al.  2011), 
so many clinicians choose to maintain patients on the drug for several months until they 
believe IH had started involuting.  This observation brought up an interesting point of 
discussion at a dissertation advisory committee meeting; it would be of interest to find 
out whether propranolol alters the natural course of IH.  In other words, propranolol 
might be able to expedite the natural course of IH, making tumors involute earlier than 
had the patient not been treated, or it might not change the natural course, but simply 
hold the tumor at bay and prevent growth until it starts to involute on its own. 
  Proliferating phase is characterized by dense, disorganized vessels, whereas 
involuting phase is characterized by enlarged, well-organized vessels.  In other words, 
vessels decrease in number but enlarge in area as IH switches from proliferating to 
involuting phase.  Histological analyses of in vivo experiments with HemECs 158 and 
Hem-Pericytes 154 showed that total vessel numbers were equivalent in the two groups 
(Figure 25C), while human CD31
+ vessels were statistically more numerous in the 
propranolol-treated group (Figure 26A).  Vessel areas were statistically equivalent for 
the groups, but numerically larger for the propranolol-treated group (Figure 26B).  In 
summary, histological analyses of in vivo experiments were inconclusive on whether or 
not propranolol could change the natural course of IH.  
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  The Bischoff Laboratory obtained IH tissues from a patient treated with 
propranolol.  Along with this tissue, other IH tissues from patients of similar age were 
selected, and their H & E slides reviewed with Dr. Harry Kozakewich, a pathologist at 
Boston Children’s Hospital.  Although the goal was to find if propranolol treatment could 
have changed tissue architecture compared to non-treated, pathology review was 
inconclusive; variabilities among individuals could have contributed to different tissue 
architecture even though ages at time of resection were similar.  In summary, it was not 
determined whether propranolol made IH involute earlier than had the patient not been 
treated, or it simply held the tumor at bay and prevented growth until it started to 
involute on its own. 
 
A case for cellular effect of propranolol in IH 
Propranolol has often been administered in oral and intravenous forms to IH patients, so 
its effects have been systemic.  Although there have been numerous reports in literature 
confirming the efficacy of propranolol in IH, some have doubted whether propranolol 
has any effect on IH itself at all.  Proponents of this hypothesis argue that the 
systemically-distributed propranolol may simply constrict vessels feeding IH, cutting off 
blood supply and eventually leading to clinical improvement.  This idea is plausible, but 
unlikely.  Researchers noted that 85-90% of IH patients experienced improvement after 
application of propranolol ointment to their lesions two or three times daily for 5 months 
(Kunzi-Rapp 2012; Xu, Lv et al.  2012).  The fact that topical application of propranolol 
improved IH suggested that its efficacy was brought on by local, not systemic, effect of 
the drug; in other words, propranolol has a cellular effect on IH.  Therefore, it is unlikely  
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that propranolol is effective in IH simply because vessels feeding IH are constricted 
without propranolol having effect(s) on IH itself. 
 
Other β-AR antagonists for IH 
Clinicians have attempted β-AR antagonists other than propranolol to treat IH.  One 
such drug is timolol, a nonselective β-AR antagonist often prescribed to decrease 
intraocular pressure in glaucoma patients.  Topical timolol treatment improved IH in 
92% of patients (Chambers, Katowitz et al.  2012).  Another example is atenolol, a 
selective β1-AR antagonist often prescribed for cardiovascular diseases.  Unlike 
propranolol, which is lipophilic, atenolol is hydrophilic, so it appears at relatively low 
concentrations in brain and is less likely to produce side effects such as nightmares and 
hallucinations.  Clinicians noted improvement of nose tip and sacral hemangiomas with 
oral atenolol treatment.  Although atenolol is a selective β1-AR antagonist, it may not be 
entirely specific for β1-AR, so it may also be able to bind β2-AR to reduce IH (Raphaël, 
de Graaf et al.  2011). 
Although neither timolol nor atenolol has been utilized as extensively as 
propranolol for treating IH, their efficacy expands the choices clinicians have in treating 
IH.  For instance, topical timolol may be prescribed for patients whose parents may be 
uneasy about systemic side effects of propranolol.  Atenolol may be prescribed for IH 
patients who also carry diagnoses of lung conditions such as asthma, in which β2-AR 
blockade is detrimental. 
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Identifying potential targets of IH:  a work in progress 
Many experiments described above revolved around β-ARs in IH, especially β2-AR.  
Although in vitro contractility assays underscored the importance of β2-AR for 
contractility of Hem-Pericytes, β-ARs may not be the only receptor for propranolol in IH.  
5-HT1B receptors have been well-characterized to function in brain, which was one of 
the reasons why β-ARs, more prevalent in rest of the body, were more extensively 
studied.  Presence of 5-HT1B receptors in IH was assessed by IHC and qRT-PCR, but a 
comprehensive evaluation to assess for their presence or absence in a spectrum of IH 
samples has not been done. 
  In addition to the possible existence of additional receptors for propranolol in IH, 
target molecules downstream of the receptors may be more numerous than those that 
are traditionally associated with β-AR.  As described above, β-AR stimulation activates 
adenylyl cyclase to increase cAMP, which activates PKA and subsequently eNOS.  
While levels of these substrates may be affected by propranolol treatment, other 
substrates may be affected, too. 
For instance, PLC cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) to 
diacylglycerol (DAG) and inositol 1, 4, 5-trisphosphate (IP3), which initiates intracellular 
calcium release and activates protein kinase C (PKC).  Phosphorylation of cytosolic 
proteins in human neutrophils by PKC was reduced upon treatment with 500 µM of 
propranolol.  PKC is not directly downstream of β-AR, so these findings suggested that 
propranolol might inhibit PKC because of its amphipathic nature rather than its 
antagonism at β-AR (Sozzani, Agwu et al.  1992).  Although concentration of 
propranolol used in these experiments was high, they hinted at existence of multiple  
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targets affected by the drug.  As noted above, proliferation of HemECs and Hem-
Pericytes was reduced by propranolol only, without epinephrine (Figure 17 A, B; Table 
5), which indicated that propranolol might be acting as an inverse agonist at β-ARs or at 
targets other than β-ARs.  PKC is an example of such a target. 
 
Future directions 
In order to clarify mechanism of propranolol in reducing IH, one needs to start by 
studying downstream molecules of β-AR and assessing whether they are affected by 
propranolol treatment.  For instance, one can assess whether changes in levels of 
cAMP can be correlated with changes in contractility of Hem-Pericytes.  If so, activation 
of PKA can be correlated with changes in levels of cAMP and eNOS. 
  As noted above, contractility assays do not show whether whole vessels contract 
in response to propranolol.  Confirmatory results from experiments on whole 
hemangioma vessels can help link cellular action of propranolol on Hem-Pericytes 
(contraction around vessels) with vascular volume reduction of hemangioma vessels as 
shown by micro-ultrasonography analyses.  Assays described in literature utilized 
optical fibers, a laser apparatus and fluorescence imaging to calculate changes in 
vessel diameters.  (Nakatani, Iwasaki et al.  2007; Bergh, Ekman, et al.  2005).  
Although vessels whose diameters (1-4 mm) might be larger than hemangioma vessels 
were used in these studies, such methods may be modified to measure hemangioma 
vessel diameter changes in response to propranolol.  One may also need to add 
epinephrine to the hemangioma vessel explant set-up to reproduce results from in vitro 
contractility assays and to emulate physiological environment.  
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Many clinicians choose to maintain patients on the drug for several months until 
they believe IH had started involuting because lesions on some patients had been 
reported to rebound after cessation of therapy.  A future experiment along the lines of 
this observation would be testing whether vascular volume, as measured by micro-
ultrasonography, increases back up after propranolol cessation.  Another future 
experiment is to assess the effect of silenced β2-AR in vivo, whether the vascular 
volume reduction from propranolol treatment would be negated or not. 
As noted above, a group of researchers hypothesized that propranolol reduces 
IH through 3 pathways- vasoconstriction, anti-angiogenesis and apoptosis (Storch and 
Hoeger 2010).  In vitro contractility assays and in vivo assays with micro-
ultrasonography pointed to vasoconstriction as a likely reason behind efficacy of 
propranolol in IH. 
On the other hand, propranolol may reduce IH via more than just 
vasoconstriction, but by a combination of effects.  To assess the possibility of anti-
angiogenesis, Shoshana Greenberger and I focused on HemSCs because they express 
the highest levels of VEGF-A among the hemangioma-derived cells.  However, possible 
anti-angiogenic activity of propranolol, with or without epinephrine, on HemECs and 
Hem-Pericytes needs to be assessed, too.  In addition, while vasoconstriction brought 
on by Hem-Pericytes may explain the immediate efficacy of propranolol within 24 hours 
of administration, decreased proliferation of HemECs and Hem-Pericytes over several 
days may be responsible for the long-term efficacy of propranolol. 
In vitro contractility assays and in vivo studies underlined the likely role of Hem-
Pericytes in the efficacy of propranolol.  Another future experiment to confirm the role of  
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Hem-Pericytes is to perform an in vivo experiment with HemECs and non-hemangioma 
pericytes such as human placental and retinal pericytes.  They did not respond to 
epinephrine and propranolol in contractility assays, so they might behave differently 
from Hem-Pericytes in vivo.  If vascular volume reduction is not noted with non-
hemangioma pericytes, then the role of Hem-Pericytes in vascular volume reduction by 
propranolol is more firmly established. 
 
Contribution to the field 
These experiments identified HemECs and Hem-Pericytes as potential cellular targets 
of propranolol in IH, which is novel because Hem-Pericytes have not been studied 
extensively, yet.  β1,2-ARs are known receptors of the drug and confirmed to be 
abundant in IH.  Proliferation of HemECs and pericytes, including Hem-Pericytes, was 
reduced by propranolol, likely through its inverse agonism at β-ARs.  Contractility of 
Hem-Pericytes was affected by propranolol, likely through its antagonism at β-ARs.  The 
importance of β2-AR in contractility of Hem-Pericytes was verified by a combination of 
β2-AR siRNA knockdown and contractility assay.  IH patients treated with propranolol 
experienced decrease in redness and firmness of lesion, which likely resulted from 
vascular volume reduction that was reproduced in vivo and verified by micro-
ultrasonography analyses.  Although mechanism of propranolol in reducing IH has not 
been clarified yet, the aforementioned findings indicate a focus on Hem-Pericytes is 
warranted and pave the way for upcoming experiments. 
  The findings described in this work are closely tied to adrenergic receptors and 
their potential relevance in IH.  As noted above, β-ARs are highly expressed in IH, both  
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in tissues and cells.  The noted reduction of proliferation of Hem-Pericytes and HemECs 
may be a result of reduction of β-AR signaling through MAPK pathway.  Although 
propranolol stimulated phosphorylation of MAPK in Chinese Hamster Ovary cells 
(Baker, Hall et al.  2003), it may do the opposite in hemangioma-derived cells.  Results 
from contractility assays also point to the likely key role of β-ARs in the actions 
accomplished by propranolol in IH.  A likely sequence of events is that epinephrine 
leads to activation of β-AR, resulting in cAMP increase and subsequent PKA activation 
in Hem-Pericytes.  PKA phosphorylates and inactivates myosin light chain kinase, which 
leads to relaxation of Hem-Pericytes on silicone.  This sequence of events is opposed 
by propranolol, so Hem-Pericytes remain contracted upon treatment with propranolol 
and epinephrine.  Therefore, these results indicated that contractility of Hem-Pericytes 
are likely influenced by signaling through β-ARs, and the key role of Hem-Pericytes in 
vascular volume reduction of hemangioma vessels was established by micro-
ultrasonography in in vivo experiments. 
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Vascular volume changes in each mouse implanted with HemSCs only 
 
 
 
 
Vascular volume changes in each mouse implanted with HemECs 158 and 
Hem-Pericytes 154 
 
 
 
 
Supplementary Figure.  Vascular volume changes for each mouse on Days 7 
and 14. 
General trend for the vehicle-treated group is similar for mice implanted with 
HemSCs only or with HemECs 158 and Hem-Pericytes 154:  vascular volume 
stayed the same or increased, with the exception of some mice. 
For the propranolol-treated group in mice implanted with HemSCs only, vascular 
volume decreased for many mice, but it stayed the same or increased for several 
others. 
For the propranolol-treated group in mice implanted with HemECs 158 and Hem-
Pericytes 154, a downward trend for most mice is easily noted.  
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